1. Cancer Biology
  2. Developmental Biology

Neural stem cell-encoded temporal patterning delineates an early window of malignant susceptibility in Drosophila

  1. Karine Narbonne-Reveau
  2. Elodie Lanet
  3. Caroline Dillard
  4. Sophie Foppolo
  5. Ching-Huan Chen
  6. Hugues Parrinello
  7. Stéphanie Rialle
  8. Nicholas S Sokol
  9. Cédric Maurange  Is a corresponding author
  1. Aix Marseille Univ, CNRS, IBDM, France
  2. Indiana University, United States
  3. Institut de Génomique Fonctionnelle, France
https://doi.org/10.7554/eLife.13463
Share this article
Cite this article
  1. Karine Narbonne-Reveau
  2. Elodie Lanet
  3. Caroline Dillard
  4. Sophie Foppolo
  5. Ching-Huan Chen
  6. Hugues Parrinello
  7. Stéphanie Rialle
  8. Nicholas S Sokol
  9. Cédric Maurange
(2016)
Neural stem cell-encoded temporal patterning delineates an early window of malignant susceptibility in Drosophila
eLife 5:e13463.
https://doi.org/10.7554/eLife.13463
  2. Download BibTeX
  3. Download .RIS

Abstract

Pediatric neural tumors are often initiated during early development and can undergo very rapid transformation. However, the molecular basis of this early malignant susceptibility remains unknown. During Drosophila development, neural stem cells (NSCs) divide asymmetrically and generate intermediate progenitors that rapidly differentiate in neurons. Upon gene inactivation, these progeny can dedifferentiate and generate malignant tumors. Here, we find that intermediate progenitors are prone to malignancy only when born during an early window of development while expressing the transcription factor Chinmo, and the mRNA-binding proteins Imp/IGF2BP and Lin-28. These genes compose an oncogenic module that is coopted upon dedifferentiation of early-born intermediate progenitors to drive unlimited tumor growth. In late larvae, temporal transcription factor progression in NSCs silences the module, thereby limiting mitotic potential and terminating the window of malignant susceptibility. Thus, this study identifies the gene regulatory network that confers malignant potential to neural tumors with early developmental origins.

https://doi.org/10.7554/eLife.13463.001

eLife digest

Some aggressive brain tumors that affect children start to form before the child is even born. These tumors often develop much more rapidly than tumors found in adults, and require fewer genetic mutations to become dangerous and invasive. However, it is not known why this happens.

Fruit flies are often used as animal models for cancer studies. As the fly brain develops, cells called neural stem cells divide several times, each time producing one stem cell and another cell known as the intermediate progenitor. The intermediate progenitor can itself divide one more time before maturing to become a neuron. Different types of neurons form in different stages of brain development. This is due to the sequential production of proteins called transcription factors in neural stem cells. Each transcription factor is inherited by a different set of intermediate progenitors and alters the activity of certain genes to determine the type of neuron the cells become.

Some genetic mutations can prevent intermediate progenitors from maturing and cause them to revert to a stem-cell-like state, which allows them to rapidly divide and form tumors. Here, Narbonne-Reveau, Lanet, Dillard et al. use fruit flies to investigate why tumors that form early on in development progress so rapidly. The experiments uncover a ‘molecular clock’ in the neural stem cells that marks out a window of time in which they generate intermediate progenitors that are prone to becoming cancerous. This clock is represented by the sequential production of transcription factors that, in addition to determining neuronal identity, also turn off various growth-promoting genes in cells as brain development proceeds. These genes sustain normal cell division, but are silenced later on to prevent cells from dividing too many times.

If the maturation of intermediate progenitors is disrupted early on in brain development while the growth-promoting genes are still active, the molecular clock fails to switch off the growth-promoting genes. As a result, these cells acquire an unlimited ability to divide, which drives tumor growth. However, later in development when the growth-promoting genes have already been switched off, disrupting the maturation of intermediate progenitors does not lead to these cells becoming cancerous.

Therefore, Narbonne-Reveau, Lanet, Dillard et al.’s findings explain why intermediate progenitors that mature early on in brain development are more prone to becoming cancerous than those that mature later, and why they need fewer mutations to become invasive. Most of the genes involved in this process are also found in humans. Therefore, the same mechanism might govern how aggressive childhood brain tumors are, which is a question for future studies to address.

https://doi.org/10.7554/eLife.13463.002

Introduction

Many pediatric tumors are thought to initiate during prenatal stages and are able to rapidly progress towards malignancy, sometimes within a few months (Marshall et al., 2014). Yet, they contain very few genetic alterations (Huether et al., 2014; Parsons et al., 2011; Pugh et al., 2013; Vogelstein et al., 2013; Wu et al., 2014) suggesting that transformation in infancy is not driven by the gradual accumulation of genetic lesions over many years, as for most adult cancers. Instead, cells born during early development appear predisposed to malignant transformation. However, the developmental programs and gene networks that govern this early malignant susceptibility remain to be deciphered (Chen et al., 2015b).

Drosophila is a well-established animal model to investigate basic principles of tumorigenesis in the developing or ageing organism (Gonzalez, 2013; Siudeja et al., 2015). In particular, it has been used to demonstrate that single gene inactivation perturbing the asymmetric divisions of neural stem cells (NSCs), called neuroblasts (NBs) in Drosophila, during development can rapidly cause NB amplification and aggressive malignant tumors in transplantation assays (Caussinus and Gonzalez, 2005; Knoblich, 2010). However, the underlying mechanisms of transformation are still unknown (Caussinus and Gonzalez, 2005; Knoblich, 2010).

Normal NBs are active from embryogenesis to pupal stages and generate the neurons and glial cells that constitute the Drosophila central nervous system (CNS). Two main types of NBs have been identified. Upon asymmetric division, most NBs (type-I) self-renew while giving rise to an intermediate progenitor, called the ganglion mother cell (GMC), which usually divides once to generate two post-mitotic neurons or glia. In contrast, a small number of NBs (type-II) located in the central brain region of the CNS, generates intermediate neural progenitors (INPs) that can produce a few GMCs allowing for an amplification of post-mitotic progeny in the lineage (Homem and Knoblich, 2012) (Figure 1—figure supplement 1A). NBs undergo a limited number of divisions during development and invariably stop dividing before adulthood (Truman and Bate, 1988). For NBs located in the ventral nerve cord (VNC) of the CNS, this limited mitotic potential is governed by a NB-intrinsic clock that schedules their terminal differentiation during metamorphosis (Maurange et al., 2008). This timing mechanism is set in NBs by the sequential expression of a series of 'temporal' transcription factors that has the ability to endow each progeny with a different neuronal identity according to their birth order (Kohwi and Doe, 2013; Maurange, 2012). In addition, NBs in the VNC need to progress up to a late temporal factor in the series to become competent to respond to the hormonal cues promoting cell cycle exit and terminal differentiation during metamorphosis (Homem et al., 2014; Maurange et al., 2008). In VNC NBs, there are four known temporal transcription factors (Hunchback (Hb) -> Kruppel (Kr) -> Pdm -> Castor (Cas)) mainly expressed during embryogenesis (Baumgardt et al., 2009; Grosskortenhaus et al., 2005; Isshiki et al., 2001; Kambadur et al., 1998). Cas is re-expressed in early larval NBs presumably followed by other, yet unknown, temporal factors required to set up a late global transition of neuronal identity during larval development and to schedule NB termination during metamorphosis (Maurange et al., 2008). Progression throughout the sequence is governed by cross-regulatory transcriptional interactions between the temporal transcription factors, and can be blocked by continuous mis-expression of a temporal factor or by its inactivation (Figure 1—figure supplement 1B) (Isshiki et al., 2001). Transitions between temporal transcription factors can also be promoted by Seven-up (Svp), an orphan nuclear receptor orthologous to mammalian COUP-TF transcription factors. In particular, Svp is transiently expressed in embryonic NBs, to promote the early Hb->Kr transition, and in larval NBs to trigger a global temporal transition allowing NBs to switch from generating an early subpopulation of neurons expressing the BTB transcription factor Chinmo to a later sub-population expressing other markers (Benito-Sipos et al., 2011; Kanai et al., 2005; Maurange et al., 2008; Mettler et al., 2006). Inactivation of Svp during early larval stages blocks NBs in an early temporal identity. Consequently, late svp-/- NBs continuously generate Chinmo+ neurons, fail to undergo terminal differentiation during metamorphosis, and continue to divide in adults (Maurange et al., 2008). Multiple series of temporal transcription factors have been uncovered in the different regions of the CNS, and recent data suggests that this temporal patterning system is evolutionary conserved and operating in mammalian NSCs (Brand and Livesey, 2011; Konstantinides et al., 2015; Li et al., 2013; Mattar et al., 2015).

Remarkably, inactivation of genes involved in the differentiation of INPs or GMCs can cause their reversion to a NB-like progenitor that, unlike normal NBs, possesses an unrestrained mitotic potential causing malignant tumors. This highly penetrant phenotype has, for example, been observed in the case of mutations inactivating the transcription factor Prospero (Pros) in GMCs (Betschinger et al., 2006; Choksi et al., 2006), or inactivating the NHL translational repressor Brat, the transcription factor Earmuff/dFezf, or components of the SWI/SNF complex in INPs (Figure 1—figure supplement 1A) (Bello et al., 2006; Betschinger et al., 2006; Eroglu et al., 2014; Koe et al., 2014; Lee et al., 2006; Weng et al., 2010). More recently, it has been described that inactivation of the transcription factors Nerfin1/INSM1 or Lola in post-mitotic neurons is sufficient to induce their progressive dedifferentiation into GMC- and NB-like states, and to cause unlimited proliferation (Froldi et al., 2015; Southall et al., 2014) (Figure 1—figure supplement 1A). While the mechanisms by which these factors induce or maintain differentiation has been thoroughly investigated and explain the observed amplification of NB-like cells upon loss-of-function, the reasons why dedifferentiated NBs (dNBs) acquire an unlimited proliferation potential remain unknown.

Here, we test the hypothesis that the unlimited mitotic potential underlying the malignant properties of dNBs is caused by the deregulation of the temporal specification system. We find that neural tumors only undergo malignant transformation if dedifferentiation is induced during an early developmental window. This early malignant susceptibility of neural cells is governed by the temporal patterning system that regulates whether or not a pre-existing early oncogenic module, that controls NB mitotic activity during development, can be co-opted to trigger malignant growth. This work therefore uncovers how the temporal transcription factor series regulates NSC mitotic potential during development and governs the malignant susceptibility of neural cells according to their birth-order. Our study provides a model that may help understand the ontogeny of human tumors with early developmental origins.

Results

Malignant tumors are propagated by a subset of dNBs that resists differentiation during metamorphosis

In order to precisely track the growth of single tumors throughout developmental and adult stages, we used the poxn-GAL4 driver to express GFP (UAS-GFP) and an RNAi construct against pros (UAS-prosRNAi) in a targeted subset of six VNC NBs from the beginning of larval development (Figure 1A,B and Figure 1—figure supplement 2). Consequently, many dNBs (Mira+) are generated at the expense of neurons (Elav+), forming six tumor-like structures of proliferating progenitors in late larval VNCs (Figure 1B and Figure 1—figure supplement 2). While wild-type (wt) NBs undergo terminal differentiation during metamorphosis and are absent in adults (Figure 1A), tumors of dNBs persist in adults and continue growing, forming in 6 day-old adults, large tumors that have fused and invaded the whole VNC (Figure 1B–D). At this stage, tracking of poxn>prosRNAi tumors generated in the VNCs shows that they invade adjacent tissues such as the central brain or halters (Figure 1C). Therefore, NB tumors induced by the loss of Pros during early larval stages and maintained in their natural environment resist differentiation cues operating during metamorphosis, and invariably acquire an unlimited growth potential as well as invasive properties. As such, we define them as malignant tumors.

Figure 1 with 3 supplements see all
Download asset Open asset
A subset of dNBs induced by Pros knock-down propagates malignant tumors in adults.

The scale bar in all images represents 30 μm. NBs and dNBs are always labeled using an anti-Mira antibody. Neurons are labelled using anti-Elav. (A) Schematic drawing representing a ventral view of the late larval (L3) and adult Drosophila CNS. Ventral nerve cord (VNC). NBs are represented as red circles. The poxn-GAL4 driver is active in six lateral NBs of the larval VNC (marked in green on the scheme). In poxn-GAL4, UAS-GFP larvae (poxn>GFP), GFP labels the six NBs (white arrows) and their recently generated progeny due to transient GAL4 and GFP perdurance. All NBs are absent in the adult VNC. (B) In poxn-GAL4, UAS-prosRNAi, UAS-GFP, UAS-dcr2 larvae (poxn>prosRNAi, GFP), six tumors of dNBs are generated. dNBs are represented on the scheme as green circles filled in red. A subset of dNBs persist and form small tumors in 1 day-old adult VNCs. (C) In 6 day-old adults, poxn>prosRNAi, GFP tumors cover the whole VNC and invade adjacent tissues such as the brain, and halteres (D) Mean tumor volumes quantified in wt poxn> GFP adult VNCs and in poxn>prosRNAi, GFP 1 and 6 day-old adult VNCs. No tumor is observed in wt adults. 1 day-old poxn>prosRNAi, GFP VNCs (n= 5 VNCs, m = 1.4x105, SEM = 6.3x104) and 6 day-old poxn>prosRNAi, GFP VNCs (n = 7 VNCs, m = 1.5x106, SEM = 1.8x105). p-value is 2.5x10-3. (E) poxn>prosRNAi, GFP tumors are almost exclusively composed of dNBs in late L3, and devoid of neurons (Elav). At around 20 hr after pupa formation, a brief pulse of neuronal differentiation in poxn>prosRNAi, GFP tumors is seen. GFP briefly labels recently differentiated Elav+ neurons due to transient GAL4 perdurance. In adults, persisting dNBs reconstitute malignant tumors.

https://doi.org/10.7554/eLife.13463.003

Tracking poxn>prosRNAi tumors throughout development revealed that a large number of dNBs undergo neuronal differentiation at around 20 hr after pupa formation (APF). At this time, a large population of GFP+ neurons (up to 79% of the tumor cell population ( ± 3%; n = 3416; 3 tumors)) could be transiently observed due to the transitory persistence of GFP from dNBs (Figure 1E). Similar figures of neural differentiation were not observed in tumors when examined during larval or adult stages. To ensure that this burst of differentiation was not inherent to the use of RNAi, nor specific to the poxn lineages, we used the MARCM technology (Lee and Luo, 1999) to generate random pros-/- clones during early larval development (L1/L2). While such clones lead to malignant tumor growth in adults (Figure 1—figure supplement 3A), a similar burst of differentiation was observed in most lineages at around 20 hr of metamorphosis (Figure 1—figure supplement 3B). Interestingly, this event coincides with the timing of wt NB terminal differentiation that occurs in response to the production of the steroid hormone (Homem et al., 2014; Maurange et al., 2008). Thus, most dNBs retain the competency to undergo differentiation like wt NBs during metamorphosis. In contrast, a subset of differentiation-resisting dNBs persists in adult to propagate malignant tumors.

A subset of dNBs aberrantly maintains the early transcription factor Chinmo

Unlimited tumor growth could be propagated by a resetting of the temporal series in newly-born dNBs. However, of the four known temporal factors in VNC NBs (Hb -> Kr -> Pdm -> Cas) and Svp, only Cas was occasionally detected in tumors observed in late larvae and in adults (Figure 2—figure supplement 1). Nevertheless, removing ectopic Cas from prosRNAi tumors did not affect the ability to generate large tumors in adults (Figure 2—figure supplement 2). Therefore, the persistence of proliferating tumors in adults is neither caused by a reset nor by a stalling at an early stage of the temporal series in dNBs. We then concentrated on Chinmo, a transcription factor known to label a sub-population of early-born neurons in type-I lineages in larvae (Maurange et al., 2008; Zhu et al., 2006), (Figure 2A). We find that Chinmo is not only expressed in early-born neurons of type-I and type-II lineages (Figure 2—figure supplement 3) but also in early NBs from which they are generated. In the VNC, Chinmo is highly expressed in early larval NBs (L1 and L2) and their progeny, but its expression in NBs progressively decreases from early L3 and is switched off in most NBs and their subsequent progeny by midL3 (Figure 2A and Figure 2—figure supplement 4). Moreover, when the late L2 pulse of Svp in NBs was abrogated, by inducing svp-/- MARCM clones in L1, in order to block temporal patterning progression, we observed that NBs failed to silence Chinmo in L3 and adults (Figure 2B). Therefore, Chinmo is a marker of early temporal identity and its window of expression in NBs is terminated in early L3 by progression of the temporal transcription factor series (Figure 2H).

Figure 2 with 5 supplements see all
Download asset Open asset
Chinmo is ectopically expressed in tumors induced by dedifferentiation.

All clones are induced in L1 (24 hr after larval hatching) using MARCM and labeled with GFP. (A) NBs in wt clones (arrows) have silenced Chinmo at late L3 stages. Note that at this stage, Chinmo remains strongly expressed in early born neurons (empty arrowheads). In adults, NBs are absents in wt clones. Chinmo is not expressed anymore in early-born neurons in adults. (B) NBs (arrows) in svp-/- clones maintain Chinmo in late L3. Chinmo is also maintained in svp-/- NBs persisting in adults and their newly generated neurons (arrow). (C) poxn NBs in late L3 have silenced Chinmo (arrows) while Chinmo expression is observed in early-born neurons (empty arrowheads). (D) A subset of poxn>prosRNAi dNBs maintains Chinmo in late L3 and adults. (E) A subset of dNBs in VNC pros-/- MARCM clones maintains Chinmo at late L3 stages. All surrounding wt NBs have silenced Chinmo (asterisks). Aberrant Chinmo expression is maintained in a subset of dNBs in adult pros-/- clones. (F) A subset of dNBs in nerfin-/- clones maintains Chinmo in late L3 and adult VNCs. (G) A subset of dNBs induced in brat-/- clones maintains Chinmo in late L3 and adult brains. (H) During early development (from L1 to mid-L3), Chinmo (purple) is expressed in NBs and early-born neurons. It is silenced in NBs during mid-larval stages by the progression of the temporal series. In svp-/- mutant NBs, Chinmo is maintained in NBs and their progeny up to adulthood. In pros-/-, nerfin-/-or brat-/- tumors, Chinmo escapes temporal regulation in a subpopulation of dNBs and remains expressed in tumors as development progresses.

https://doi.org/10.7554/eLife.13463.007

Interestingly, while Chinmo is silenced in poxn NBs in late L3 (Figure 2C), we observed that a minor subset of dNBs in poxn>prosRNAi tumors retained Chinmo expression (Figure 2D). Ectopic expression of Chinmo in about 20% of dNBs was also observed in tumors that persist in adults (Figure 2D and Figure 2—figure supplement 5). Moreover, aberrant expression of Chinmo in dNBs is not specific to the poxn lineage as it can be observed in L3 and adult pros-/- MARCM clones induced in L1 from random NBs (Figure 2E). Thus, in pros-/- tumors induced during early larval stages, chinmo in a subset of dNBs appears to escape regulation by the temporal series and fails to be silenced at the appropriate time (Figure 2H). Similar aberrant temporal expression of Chinmo was also observed in tumors originating from the dedifferentiation of immature neurons in nerfin1-/- MARCM clones (Figure 2F) and in tumors originating from the dedifferentiation of INPs in brat-/- MARCM clones from type-II NB lineages (Figure 2G). Thus, ectopic Chinmo expression appears to be a common feature of neural tumors induced during early larval stages by dedifferentiation (Figure 2H).

Chinmo promotes resistance to differentiation and is necessary to sustain tumor growth

To test whether Chinmo’s aberrant expression in dNBs contributes to tumorigenesis, we co-expressed chinmoRNAi and prosRNAi transgenes in random NB clones induced during early larval stages, or from different GAL4 drivers active in specific NB subsets. In all cases, despite efficient chinmo silencing (Figure 3—figure supplement 1A), the presence of supernumerary Mira+ cells found dividing in late L3 larvae demonstrated that Chinmo was dispensable for dedifferentiation and initial NB amplification upon loss of Pros (Figure 3A,B and Figure 3—figure supplement 1B,C). However, we find that prosRNAi, chinmoRNAi tumors are smaller than prosRNAi tumors in late L3 larvae (Figure 3A,B, Figure 3—figure supplement 1C,D), due to smaller and fewer dNBs that exhibited a decreased mitotic index (Figure 3D, Figure 3—figure supplement 1E–G). In contrast, forced expression of Chinmo (using UAS-chinmo) in a prosRNAi context enhanced the size of tumors in late L3 larvae, which contained larger dNBs (Figure 3—figure supplement 1D,E). These results show that Chinmo promotes cell growth and proliferation within tumors.

Figure 3 with 3 supplements see all
Download asset Open asset
Chinmo sustains tumor growth beyond developmental stages.

All clones were induced in L1/L2. (A) Expression of prosRNAi in Flp-out clones induces malignant tumors, covering the VNC in adults. (B) Expression of both prosRNAi and chinmoRNAi in Flp-out clones induces tumors that fail to grow further in the adult VNC. (C) Mean tumor volume in Flp-out prosRNAi and prosRNAi;chinmoRNAi clones induced during early larval stages quantified in the VNC of wandering L3 (wL3), 1 day-old and 6 day-old adults. wL3: prosRNAi (n = 6 VNCs, m = 7.4x104, SEM=2.1x104), prosRNAi;chinmoRNAi (n = 7 VNCs, m = 2.3x104, SEM = 5.7x103); 1 day-old adult: prosRNAi (n = 3 VNCs, m = 4.7x105, SEM = 2.5x104), prosRNAi;chinmoRNAi (n = 5 VNCs, m = 9.5x104, SEM = 2.5x104); 6 day-old adult: prosRNAi (n = 5 VNCs, m = 1.5x106, SEM = 2.1x105), prosRNAi;chinmoRNAi (n = 6 VNCs, m = 2.4x105, SEM = 1.9x105). p-values are respectively 2.2x10-2, 3.6x10-2 and 8.7x10-3. (D) Mean percentage of PH3+ dNBs in late L3 and 1 day-old adult Flp-out prosRNAi and prosRNAi;chinmoRNAi induced during early larval stages. Late L3: prosRNAi (n = 7 VNCs, m = 11.64, SEM=0.99), prosRNAi;chinmoRNAi (n = 6 VNCs, m = 8.06, SEM = 0.92); 1 day-old adult: prosRNAi (n = 4 VNCs, m = 10.92, SEM = 0.79), prosRNAi;chinmoRNAi (n = 4 VNCs, m = 1.97, SEM = 0.50). p-values are respectively 1.4x10-2 and 2.9x10-2; p-value between prosRNAi;chinmoRNAi wL3 and 1-day old adults is 9.5x10-3. (E) Tumorigenic growth after transplantation of VNCs is assessed by the presence of GFP in the abdomen of transplanted flies after 7 days (p-value is 6.0x10-6). (F) MARCM brat-/-, chinmo-/- clones induced during early larval stages generate tumors (Mira) in late L3. However, most clones undergo complete neuronal differentiation during metamorphosis, as shown with an absence of dNBs and large ectopic axonal bundles in adult clones (inset). Occasional remaining dNBs are not able to reconstitute large tumors (inset). Below, brat-/-, chinmo-/- clones are represented schematically during development. (G) MARCM brat-/- clones induced during early larval stages rapidly leads to large malignant tumors in the adult brain. (H) Mean tumor volumes in MARCM brat-/- and brat-/-, chinmo-/- clones induced during early larval stages quantified in 6 day-old adult central brains. MARCM brat-/- clones (n = 4 brains, m = 3.0x106, SEM = 1.0x106) and MARCM brat-/-, chinmo-/- clones (n = 13 brains, m = 7.1x104, SEM = 3.3x104). p-value is 8.4x10-4. (I) Overexpression of chinmo in Flp-out clones induces NB amplification in larvae (yellow dotted line), giving rise to tumors composed of proliferating dNBs in adults.

https://doi.org/10.7554/eLife.13463.013

Importantly, a higher proportion of dNBs is converted to neurons in prosRNAi, chinmoRNAi tumors compared to prosRNAi tumors during metamorphosis (Figure 3—figure supplement 1B,H). Consistently, adult persistence of tumors originating from prosRNAi, chinmoRNAi clones induced in L1/L2 is reduced by about 30% compared to prosRNAi clones (Figure 3—figure supplement 2A). This indicates that Chinmo confers resistance to the differentiation cues operating during metamorphosis. Additionally, persisting prosRNAi; chinmoRNAi tumors are smaller and fail to grow further, or completely differentiate, in 6 day-old adults, while prosRNAi control clones rapidly invade the CNS (Figure 3A–C and Figure 3—figure supplement 2B). Failure to grow is, at least, partly due to a low mitotic activity within prosRNAi; chinmoRNAi adult tumors, as already observed in larval tumors. Moreover, the mitotic rate in prosRNAi; chinmoRNAi tumors decreases from larval to adult stages, while remaining stable in prosRNAi tumors (Figure 3D), in 6 day-old adults, prosRNAi; chinmoRNAi dNBs sometimes show cytoplasmic extensions characteristic of quiescence (Chell and Brand, 2010; Truman and Bate, 1988) (Figure 3—figure supplement 2C). Together, these experiments suggest that dNBs in prosRNAi; chinmoRNAi tumors progressively exhaust their proliferation potential. The decreased growth potential of prosRNAi; chinmoRNAi tumors was confirmed with the conventional transplantation assay (Rossi and Gonzalez, 2015) with only 16% (n=20) of VNCs developing large tumors in the abdomen of transplanted animals after 7 days, compared to 84% (n=32) with prosRNAi VNCs (Figure 3E). We also assessed the mitotic index of the Chinmo+ and Chinmo- dNBs present within the same prosRNAi tumor. We found that it was significantly higher for the subpopulation of Chinmo+ dNBs than for Chinmo- dNBs suggesting that two types of progenitors with different mitotic potential co-exist in tumors (Figure 3—figure supplement 3).

We then tested whether Chinmo was also essential for the growth of brat-/- tumors. Like brat-/- MARCM clones (Figure 2G), brat-/- chinmo-/- MARCM clones induced in L1 led to large clones with amplified NBs in late L3 (Figure 3F). However, while brat-/- MARCM clones led to large tumors partly covering the adult brain in 6 day-old adults (Figure 3G), brat-/- chinmo-/- MARCM clones differentiated during metamorphosis and occasional remaining dNBs were unable to reconstitute large tumors in adults (Figure 3F,H). Thus, these results collectively indicate that ectopic Chinmo in a subset of dNBs boosts cell growth, counteracts neuronal differentiation during pupal stages, and is required for sustained proliferation once development is terminated.

To further investigate Chinmo’s ability to promote cell growth and proliferation on its own, we over-expressed it in wt NBs clones from early larval stages. Although Chinmo does not induce proliferation when expressed in post-mitotic neurons (Zhu et al., 2006), we found that clonal overexpression of UAS-chinmo in wt NBs and GMCs from early L1 is sufficient to induce NB amplification in 60% of NB clones (6 VNCs, 37 clones) and the formation of tumors that resist differentiation during metamorphosis and continue proliferating in adults (Figure 3I). Because adult flies containing UAS-chinmo clones rapidly die, we could not test the long-term growth potential of UAS-chinmo NB tumors. To circumvent this problem, we transplanted larval VNCs over-expressing Chinmo in all NBs (nab>chinmo). We found that 26% of transplanted flies grow large tumors in the abdomen after 7 days (Figure 3E) showing that Chinmo over-expression in NBs and their GMCs is sufficient to induce sustained tumorigenic growth. Together, these data demonstrate that aberrant Chinmo expression in a subset of dNBs is oncogenic and drives sustained tumor growth beyond developmental stages.

Chinmo boosts protein biosynthesis and expression of the mRNA-binding proteins Imp and Lin-28

To explore Chinmo’s mode of action, we compared, by RNA-seq, the transcription profiles of late larval VNCs in which all NBs express the prosRNAi construct (nab>prosRNAi) with prosRNAi VNCs in which Chinmo was either knocked down or over-expressed (respectively nab>prosRNAi, chinmoRNAi and nab>prosRNAi, chinmo) (Figure 4A). Two hundred and fourteen genes were both up-regulated in the nab>prosRNAi, chinmo condition and down-regulated in the nab>prosRNAi, chinmoRNAi condition when compared to the nab>prosRNAi control (p-value < 0.05). They were considered as putative targets positively regulated by Chinmo. On the other hand, 388 genes were both downregulated in the nab>prosRNAi, chinmo condition and up-regulated in the nab>prosRNAi, chinmoRNAi condition compared to the nab>prosRNAi control (p-value<0,05) (Figure 4—source data 1). They were considered as putative targets negatively regulated by the presence of Chinmo. Gene ontology (GO) and KEGG pathway analyses indicate that negative targets are highly enriched in genes involved in neuronal differentiation consistent with the ability of Chinmo to prevent dNB differentiation during metamorphosis (Figure 4B and Figure 4—figure supplement 1). In contrast, positive targets are enriched in genes involved in ribosome biogenesis, RNA and DNA metabolism, DNA replication and cell-cycle progression (Figure 4B and Figure 4—figure supplement 1). These data support a role for Chinmo in promoting dNB growth and mitotic activity that is consistent with our genetic and proliferation assays (Figure 3).

Figure 4 with 2 supplements see all
Download asset Open asset
Chinmo promotes Imp and Lin-28 expression.

(A) prosRNAi is expressed in all larval NBs using nab-GAL4. RNA-seq indicated 214 genes to be commonly up-regulated, and 388 genes were found to be commonly downregulated, when comparing nab>prosRNAi vs. nab>prosRNAi, chinmoRNAi and nab>prosRNAi, chinmo vs. nab>prosRNAi (adj p-value < 0.05). (B) Graphical representation of the log2 fold change as a function of the base mean expression of Chinmo targets, comparing nab>prosRNAi, chinmo to nab>prosRNAi, chinmoRNAi. lin-28, Imp and chinmo are highlighted in red. (C) Lin-28, Imp (cytoplasmic) and Chinmo (nuclear) are co-expressed in the same subset of dNBs in poxn>prosRNAi larval and adult tumors (delineated with the yellow dashed lines). (D) Clonal mis-expression of Chinmo in GFP+ Flp-out clones induced in L1, delimited by yellow dashed lines, induces Imp and Lin-28 co-expression in dNBs.

https://doi.org/10.7554/eLife.13463.017
Figure 4—source data 1

Differentially expressed genes and enriched GO terms and KEGG pathways between prosRNAi tumors expressing various levels of Chinmo.

(A) Differentially expressed genes between nab>prosRNAi and nab>prosRNAi, chinmoRNAi late larval VNCs (p-value > 0,05). (B) Differentially expressed genes between nab>prosRNAi, chinmo and nab>prosRNAi late larval VNCs (p-value > 0,05). (C) List of genes that are commonly up- and down-regulated when comparing nab>prosRNAi vs. nab>prosRNAi, chinmoRNAi VNCs and nab>prosRNAi, chinmo and nab>prosRNAi VNCs. (D) Differentially expressed genes between nab>prosRNAi, chinmo and nab>prosRNAi, chinmoRNAi late larval VNCs (p-value > 0,05). (E) Enriched KEGG pathways for commonly up-regulated genes (see C). (F) Enriched GO for up-regaled and down-regulated genes.

https://doi.org/10.7554/eLife.13463.018

Among the 214 positive targets of Chinmo uncovered by RNA-seq, several genes are important regulators of malignancy in mammals such as lin-28 (Molenaar et al., 2012), IGF-II mRNA-binding protein (Imp) (Lederer et al., 2014),musashi (msi) (Wang et al., 2010), Aldehyde dehydrogenase (Aldh) (Ginestier et al., 2007), and snail (sna) (Barrallo-Gimeno and Nieto, 2005) (Figure 4—figure supplement 1, Figure 4—source data 1). Among them, the most highly up-regulated genes, when comparing the nab>prosRNAi, chinmo vs. nab>prosRNAi, chinmoRNAi conditions, are two mRNA-binding proteins Lin-28 (64 fold) and Imp (10 fold) (Figure 4B, Figure 4—figure supplement 1, Figure 4—source data 1). Lin-28 and Imp are highly conserved oncofoetal genes in humans (Bell et al., 2013; Lederer et al., 2014) and have recently been shown to be co-expressed in embryonic NSCs in mice (Yang et al., 2015). We validated their expression in tumors by immunostaining. Interestingly, in larval and adult prosRNAi tumors, both Imp and Lin-28 are present in the cytoplasm of the subset of dNBs that co-express Chinmo (Figure 4C). Furthermore, clonal overexpression of UAS-chinmo induces supernumerary NBs that express both Imp and Lin-28, while small prosRNAi,chinmoRNAi or brat-/- chinmo-/- tumors in adults lack Imp (not tested for Lin-28) (Figure 4D and Figure 4—figure supplement 2). Together, these experiments demonstrate that Imp and Lin-28 are, direct or indirect, positive targets of Chinmo in tumors.

Imp sustains Chinmo expression in dNBs and tumor growth

In mammals, the three orthologs of Imp (IMP1-3, also called IGF2BP1-3) are believed to be important regulators of tumorigenesis, but their function and targets are unclear (Bell et al., 2013). We find that overexpression of Imp in NBs is not sufficient to induce their amplification and tumorigenesis (Figure 5—figure supplement 1). Moreover, efficient Imp knock-down using one or two different ImpRNAi transgenes (ImpRNAi1 or ImpRNAi1;2) in poxn>prosRNAi larvae did not prevent initial NB amplification, although tumor growth appeared slowed (Figure 5A,B and Figure 5—figure supplement 2A,B). Strikingly, most prosRNAi, ImpRNAi tumors failed to maintain continuous growth and remained small in 6 day-old adults (Figure 5B–C). Thus Imp is required for sustained tumor growth.

Figure 5 with 3 supplements see all
Download asset Open asset
Imp sustains Chinmo expression in tumors.

(A) Chinmo is expressed in a subset of dNBs in both larval (dashed yellow lines) and adult poxn>prosRNAi tumors (see enlargement). (B) Chinmo is still expressed in a subset of dNBs in larval poxn>prosRNAi, ImpRNAi tumors but is progressively lost in adult tumors that remain small (see enlargement). poxn>prosRNAi, Imp tumors tend to have an increased number of Chinmo+ cells (not quantified). (C) Mean tumor volume of 6 day-old adults in poxn>prosRNAi, poxn>prosRNAi; ImpRNAi1;2 and poxn>prosRNAi; Imp. poxn>prosRNAi (n = 6 VNCs, m = 1.1x106, SEM = 1.3x105), poxn>prosRNAi; ImpRNAi1;2 (n = 8 VNCs, m = 9.5x104, SEM = 2.4x104), poxn>prosRNAi; Imp (n = 6 VNCs, m = 1.0x106, SEM = 1.3x105). p-values are respectively 6.7x10-4 and 0.82.

https://doi.org/10.7554/eLife.13463.021

A recent study has shown that Imp post-transcriptionally promotes Chinmo expression in mushroom body neurons (Liu et al., 2015). We thus sought to assess Chinmo expression in prosRNAi tumors lacking Imp. We find that Chinmo+ dNBs are still present in larvae. However, they are absent from many tumors in 6 day-old adults (12 out of 22 with ImpRNAi1, and 11 out of 14 with ImpRNAi1;2) (Figure 5A,B). Similar results are obtained with tumors grown for 10 days in larvae fed with a sterol-free diet that has been shown to prevent pupariation (Katsuyama and Paro, 2013; Parkin and Burnet, 1986). In such conditions, poxn>prosRNAi tumors grow extensively and invade the central brain and optic lobes, while poxn>prosRNAi, ImpRNAi1;2 tumors remain much smaller, stay localized to the VNC and show an almost complete loss of Chinmo+ dNBs (Figure 5—figure supplement 3A,B). We also noted a tendency for an increased number of Chinmo+ dNBs in 4 day-old adults upon Imp over-expression (Figure 5B, not quantified). These experiments indicate that Imp is not required to establish the initial population of Chinmo+ dNBs but is necessary for their long-term maintenance in tumors. Together with the transcriptional activation of Imp by Chinmo, these experiments reveal a positive feedback loop between Chinmo and Imp necessary for sustained tumor growth beyond developmental stages.

Lin-28 boosts Chinmo expression within tumors

In contrast to Imp, loss of Lin-28 does not appear to impair the self-renewal of Chinmo+ dNBs and the growth of pros-/- or brat-/- tumors induced in L1 (tumor size quantified in adults) (Figure 6—figure supplement 1). This suggests that Lin-28 is dispensable for Chinmo expression and for sustained tumor growth. However, while mis-expression of Drosophila lin-28 in wt larval NB clones is not sufficient to induce NB amplification and ectopic expression of Chinmo and Imp (Figure 6—figure supplement 2), we find that overexpression of Drosophila lin-28 in prosRNAi tumors from their initiation leads to a significant increase in the proportion of Chinmo+ dNBs and an overall increase in the intensity of Chinmo expression when observed in 6 day-old adults (Figure 6A–C; Figure 6—figure supplement 3). Moreover, Imp is co-expressed in all Chinmo+ dNBs. This suggests that overexpression of Lin-28 in the tumorigenic context is able to favor the self-renewing capacity of Chinmo+/Imp+ dNBs at the expense of Chinmo-/Imp- dNBs. Interestingly, overexpression of mammalian LIN28A and LIN28B is often associated with malignant tumors in human (Carmel-Gross et al., 2016; Molenaar et al., 2012; Viswanathan et al., 2009). Remarkably, human LIN28A and LIN28B, mis-expressed in Drosophila poxn>prosRNAi tumors, have retained the ability to strongly enhance Chinmo expression within tumors, demonstrating evolutionary-conserved interactions between Lin-28 and Chinmo or its regulators (Figure 6A–C). All together, these data identifies Chinmo and Imp as a core oncogenic module that sustains dNB proliferation and tumor growth beyond developmental stages. In addition, expression of this module is boosted by high levels of Lin-28 in tumors (Figure 6D, Figure 6—figure supplement 4).

Figure 6 with 4 supplements see all
Download asset Open asset
Chinmo, Imp and Lin-28 form an oncogenic loop.

(A) Chinmo expression in 5 day-old adult VNCs color-coded relative to staining intensity. All transgenes are expressed with the poxn-GAL4 driver. Humanized tumors mis-express human LIN28A or LIN28B. (B) Ratio representing the volume of Chinmo+ cells over the total tumor volume in 5 day-old adult VNCs. poxn>prosRNAi (n = 4 VNCs, m = 0.188, SEM = 0.017), poxn>prosRNAi, dlin-28 (n = 6 VNCs, m = 0.583, SEM = 0.072) and poxn>prosRNAi, LIN28A (n = 8 VNCs, m = 0.474, SEM = 0.060). p-values are respectively 9.5x10-3 and 8.0x10-3. (C) Mean Chinmo intensity in Chinmo+ cells. poxn>prosRNAi (n = 7 tumors, m = 962, SEM = 37), poxn>prosRNAi, dlin-28 (n = 8 tumors, m = 1413, SEM = 125) and poxn>prosRNAi, UAS-LIN28A (n = 9 tumors, m = 1236, SEM = 110). Each sample is the mean of 3 different focal sections of the same tumor. p-values are respectively 5.9x10-3 and 7.1x10-2. (D) Representation of the observed cross-regulatory interactions composing the oncogenic module.

https://doi.org/10.7554/eLife.13463.025

The temporal series silences chinmo, Imp and lin-28 (CIL genes) in late NBs to limit their mitotic potential

We then wondered whether Chinmo, Imp and Lin-28 (CIL) co-expression is specific to dNBs or can be found during development. Interestingly, in the VNC and central brain, both Imp and Lin-28 are co-expressed with Chinmo in normal NBs and their surrounding neuronal progeny from L1 to early L3. From early L3, they are then progressively downregulated together with Chinmo in NBs and subsequent progeny (Figure 7A). Lin-28 and Chinmo remain transiently expressed in early-born neurons up to midL3 and early pupal stages respectively, while Imp expression in early-born neurons perdures in adult (Figure 7—figure supplement 1). However, Imp and lin-28, like chinmo, fail to be silenced in late larval and adult NBs with a stalled temporal series (svp-/-), as well as in their progeny (Figure 7B). Thus, the temporal system silences chinmo, Imp and lin-28 in L3 NBs. We then tested the function of Chinmo in NBs during development. chinmo-/- MARCM clones were induced during embryogenesis in order to ensure the removal of Chinmo during the entire post-embryonic period (Figure 7C). In chinmo-/- late L3 clones, we did not observe a difference in clone size in the VNC compared to the control wt clones (Figure 7D) and chinmo-/- NBs exhibit the same mitotic rate and possess the same size as wt NBs in late L3 (Figure 7E,F). Thus Chinmo is dispensable for NB growth and proliferation during larval development. We then tested whether temporally blocked NBs persist in adults due to the maintenance of Chinmo, Imp and Lin-28. Knocking-down Chinmo in temporally stalled svp-/- NBs is not sufficient to prevent adult persistence, although NB growth is impaired (Figure 7G,H and Figure 7—figure supplement 2A). However, knocking down both Chinmo and Imp in svp-/- NBs restores their elimination before adulthood (Figure 7G,H). This suggests that the Chinmo/Imp module is necessary to maintain the unlimited mitotic potential of NBs stalled in an early temporal identity (Figure 7H). Together with our results showing that over-expression of Chinmo is sufficient to induce persistence of NBs in adults (Figure 3H), these experiments also indicate that silencing of Imp and chinmo by the temporal patterning system may be necessary to limit NB mitotic activity and schedule the competency for NB terminal differentiation during metamorphosis (Figure 7H).

Figure 7 with 2 supplements see all
Download asset Open asset
The temporal series silences chinmo, Imp and lin-28 in NBs for their timely termination during development.

(A) Chinmo, Lin-28 and Imp are coexpressed in wt VNC NBs in L2, and are silenced in NBs in late L3. Note that in late L3, surrounding early-born neurons keep expressing Imp and Chinmo whereas Lin-28 is down-regulated in all cells. (B) Imp is maintained in L1-induced MARCM svp-/- NBs (GFP+) in late L3. Lin-28 and Imp are maintained in MARCM svp-/- NBs (GFP+) that persist in adult. (C) wt and chinmo-/- MARCM clones induced during embryogenesis. (D) Number of cells per clone in late L3 in VNC wt and chinmo-/- MARCM clones induced during embryogenesis. wt MARCM 40A (n = 16 clones, m = 82, SEM = 4.7); chinmo-/- MARCM clones (n=17 clones, m = 83, SEM = 4.8). p-values is 0.88. (E) Mean NB area in late L3 VNC wt and chinmo-/- MARCM clones induced during embryogenesis. wt MARCM 40A (n = 45 NBs, m = 76.7, SEM = 3.2), chinmo-/- MARCM clones (n = 46 NBs, m = 76.3, SEM = 2.9). p-value is 0.88. (F) Mean percentage of PH3+ NBs in late L3 VNC MARCM wt and chinmo-/- clones induced during embryogenesis. wt clones (n = 4 VNCs, m = 20.6, SEM = 1.43), chinmo-/- clones (n = 4 VNCs, m = 20.8, SEM = 2.23), p-value is 0,88. (G) NBs persist in adult MARCM svp-/-, chinmoRNAi clones induced in L1. NBs are smaller (Figure 7—figure supplement 1A) and maintain Imp expression. Removing both Chinmo and Imp (chinmoRNAi, ImpRNAi) in a svp-/- MARCM clone is sufficient to restore NB elimination before the end of development. (H) Schematic recapitulation of the above experiments.

https://doi.org/10.7554/eLife.13463.030

Surprisingly, in contrast to tumors, Chinmo knock-down in svp-/- MARCM clones does not lead to the down-regulation of Imp (Figure 7G and Figure 7—figure supplement 2B). This shows that Imp expression in early-identity NBs does not require Chinmo. Thus, expression of chinmo and Imp in NBs during development and tumorigenesis are not subordinated to the same cross-regulatory interactions.

Malignant tumors can only be induced during the early CIL+ expression window

We then tested whether ectopic expression of CIL proteins in pros-/- tumors was due to aberrant maintenance from an early CIL+ cell of origin. We induced pros-/- tumors by MARCM in the VNC either early (during L1/L2) when Chinmo is still expressed in NBs and their progeny, or at midL3 after the CIL module has been switched off by temporal factor progression. One day after induction, ectopic Chinmo is observed in 91% of L1/L2-induced tumors (n = 65). In contrast, Chinmo is not detected 1 day after induction in midL3-induced tumors (n = 54) (Figure 8A), or 3 days after induction when larvae are grown in the sterol-free medium that prevent pupariation (26 out of 27 tumors still lack Chinmo) (Figure 8B, Figure 8—figure supplement 1). Thus, Chinmo+ dNBs are only present in pros-/- tumors initiated during an early window of development (before midL3).

Figure 8 with 2 supplements see all
Download asset Open asset
pros-/- tumors induced in the VNC of midL3 larvae do not express Chinmo and do not grow in adults.

(A) One day after early (L1/L2), induction most dNBs from pros-/- clones retain Chinmo expression. In contrast, Chinmo is absent from dNBs 1 day after late (midL3) clonal induction. (B) Three days after L1/L2-induction in larvae raised on the sterol-free diet, pros-/- clones contain Chinmo+ dNBs (54 out of 59). In contrast, 3 days after mid-L3 induction on the sterol-free diet, pros-/- clones do not contain Chinmo+ dNBs (26 out of 27). (C) Adult VNC containing L1/L2-induced pros-/- MARCM clones are covered by tumors. In contrast, midL3-induced pros-/- MARCM clones are rare and remain small in adult VNCs. (D) On the sterol-free diet, 7 days after L1/L2-induction, pros-/- clones keep proliferating and generate large tumors of GFP+ dNBs (Mira shown in red) that cover the whole CNS. In contrast, pros-/- clones, 7 days after midL3-induction, rapidly stop growing and dNBs exhibit quiescence markers such as the loss of GFP and cytoplasmic extensions (arrow emphasizes cytoplasmic extensions from dNBs, arrowhead emphasizes a cytoplasmic extension from a wt NB).

https://doi.org/10.7554/eLife.13463.033

We then investigated the malignant potential of L1/L2- and midL3-induced tumors. L1/L2-induced pros-/- clones persist in 100% of adults and rapidly progress to cover the totality of the VNCs (n>100). In contrast, midL3-induced tumors persist in only 36.4% of adult VNCs (n = 19) (Figure 8C), and make an average of 0.63 persisting tumor per adult VNC (SEM = 0.23), deriving from an average of 13.5 tumors per larval VNCs (n= 16, SEM = 1). These rare persisting tumors (4,7%) in adult VNCs remain small, containing no more than 100 dNBs. Thus, most midL3-induced tumors differentiated during metamorphosis, and the few tumors that persist in adults possess a limited growth potential (Figure 8C). This limited growth potential of midL3-induced tumors was also observed when larvae were maintained in the sterol-free diet for 7 days after induction. In such conditions, midL3-induced tumors rapidly stop growing, with many dNBs progressively losing GFP expression, suggesting reduced transcriptional activity, and exhibiting reduced mitotic index and cytoplasmic extensions typical of quiescent NBs indicating a progressive exhaustion of their mitotic potential (Chell and Brand, 2010; Sousa-Nunes et al., 2011; Truman and Bate, 1988) (Figure 8D, Figure 8—figure supplement 1, 2A,B). Similar features are observed in surrounding wt NBs that do not undergo terminal differentiation in the absence of pupal signals (Figure 8—figure supplement 1, and Figure 8—figure supplement 2B,C). In contrast, L1/L2-induced tumors remain highly proliferative leading to massive dNB tumors covering the whole CNS (Figure 8D). Together these results indicate that malignant pros-/- tumors can only be induced if they are initiated during an early window of development (before midL3) while NBs and their progeny express the CIL module. In contrast, dNBs induced by the dedifferentiation of late-born CIL-negative GMCs cannot reactivate Chinmo expression, possess a limited proliferation potential and undergo terminal differentiation during metamorphosis like wt NBs, or persist as benign, slow-growing, tumors in adults.

The temporal identity of a cell determines its malignant susceptibility

These results suggest that the silencing of the CIL genes in late-born neural cells by temporal patterning progression may abolish their malignant potential upon dedifferentiation. Alternatively, absence of CIL reactivation in late-induced tumors could be due to a non-permissive microenvironment subsequent to developmental progression. To distinguish these possibilities, we combined the GAL80ts system (McGuire et al., 2004) and MARCM to temporally control the induction of prosRNAi tumors in svp-/- NB clones blocked in an early temporal identity. Loss of Svp was induced in L1 by a 45 min heat-shock. Then larvae were kept at 18°C in the control experiment, or switched to 29°C from late L3 or pupal stages for late induction of prosRNAi. While adult flies raised at 18°C possess a single NB per clone due to the early loss of Svp, flies raised at 29°C from L3 or pupal stages contain large tumors of CIL+ dNBs in their VNCs (Figure 9A,B). Thus, the GMCs of NBs blocked in an early temporal identity remain predisposed to generate CIL+ malignant tumors independently of the developmental stage. These results demonstrate that the malignant potential of a neural cell undergoing dedifferentiation is dictated by its temporal identity, and blocking temporal factor progression in NBs extends the window of malignant susceptibility.

Figure 9
Download asset Open asset
The temporal series regulates the malignant susceptibility of neural cells born during development.

(A) Larvae were raised at 18°C and heat-shocked in L1 to induce svp-/- MARCM clones. Controls were kept at 18°C, to prevent prosRNAi expression, leading to the persistence of a single NB per clone in adults. In contrast, if larvae are switched to 29°C from late L3, prosRNAi is expressed leading to large tumors in adults, exclusively composed of dNBs expressing Chinmo, Imp and Lin-28. (B) Schematic recapitulation of the above experiments. Blocking temporal progression in NBs extends the window of malignant susceptibility.

https://doi.org/10.7554/eLife.13463.036

Discussion

In this study, we have uncovered that the NB-encoded temporal patterning system delineates an early window of malignant susceptibility (Figure 9B) through the regulation of an early growth module involving Chinmo, Imp/IGF2BP and Lin-28. Here, we discuss how our work supports an ancestral model that may explain the rapid malignant progression of neural tumors induced during early development.

An oncogenic module defining growth-sustaining cells in neural tumors with early developmental origins

We have demonstrated that the unlimited growth potential of pros-/- and brat-/- tumors induced during early larval development relies on the aberrant maintenance of an oncogenic module respectively co-opted from dedifferentiating early-born GMCs and INPs (and possibly neurons in nerfin1-/- tumors). The core components of the module involve the BTB transcription factor Chinmo and the mRNA-binding protein Imp. Chinmo and Imp positively cross-regulate at the transcriptional and translational level respectively. We find that Chinmo is a proto-oncogene that is able to promote the transcription of a large set of genes that boost protein synthesis and cell-cycle progression, and is also a strong repressor of neural differentiation. Consequently, over-expression of Chinmo in NBs and GMCs, but not in neurons (Zhu et al., 2006), is sufficient to cause NB amplification and tumor growth. This is consistent with a previously identified oncogenic activity of Chinmo when expressed in the hematopoietic and imaginal disc precursors (Doggett et al., 2015; Flaherty et al., 2010). In contrast, Imp mis-expression is not sufficient to trigger NB amplification but Imp is necessary to maintain pros-/- tumor growth beyond developmental stages, at least partly by allowing/sustaining Chinmo expression. Another mRNA-binding protein, Lin-28, is also positively regulated by Chinmo in tumors. We found that Lin-28 is however dispensable for tumor growth although Lin-28 over-expression enhances the proportion of Chinmo+ dNBs in tumors. Thus Lin-28 overexpression may promote the self-renewal of Chinmo+, Imp+ dNBs and therefore increase the growth potential of the tumor. This role is consistent with the observation that high expression of LIN28 isoforms in human tumors promotes tumor growth (Viswanathan et al., 2009). Interestingly, a recent RIP-seq analysis in Drosophila embryos has uncovered both Imp and chinmo mRNAs among the most highly enriched targets of Lin-28 (Chen et al., 2015a), and mammalian Imp and Lin-28 orthologs share many common RNA targets (Yang et al., 2015). Thus, Imp and Lin-28 may also directly co-regulate Chinmo translation in tumors. Further investigation is required to identify all components and the regulatory principles of this oncogenic network.

Collectively, our results imply that, although representing a minor sub-population of dNBs, the subset of dNBs co-expressing Chinmo, Imp, and Lin-28 (CIL+ dNBs) is sustaining the unlimited growth of the tumor. It remains to be demonstrated whether these CIL+ dNBs act as cancer stem cells (CSCs) (Beck and Blanpain, 2013), able to self-renew and generate the bulk of the tumor, or represents a transient amplifying population of progenitors born from another population of rare and slow-proliferating CSCs.

Temporal regulation of NSC mitotic potential during development

We have shown that Chinmo, Imp and Lin-28 are co-expressed in early NBs and their progeny and are silenced shortly after the L2/L3 transition in ageing NBs by progression of the temporal transcription factor series. Surprisingly, although Chinmo promotes tumor growth during both larval and adult stages, loss of Chinmo in normal NBs did not significantly affect the total number of progeny generated at the end larval stages. This indicates that the growth and proliferation of normal NBs and dNBs does not exhibit the same dependency on Chinmo.

Although Chinmo is not required for proper NB mitotic activity in larvae, its over-expression in NBs is sufficient to promote tumorigenic growth in adults. Moreover, NBs blocked in an early temporal identity fail to persist in adults if lacking Imp and Chinmo. Thus, our results suggests that the silencing of Chinmo and Imp in early L3 by the temporal series is a way to limit the mitotic potential of NBs and ensure their timely termination during pupal stages. The role of Lin-28 in regulating NB mitotic activity during development is still unknown, but in mice, Imp1/Igf2bp1 and Lin28a/b are co-expressed in fetal cortical progenitors where they post-transcriptionally regulate growth genes involved in the PI3K/TOR pathway (Yang et al., 2015). This suggests an evolutionary conserved growth-promoting role of these factors during neural development. Moreover, Lin28a and Imp1 are downregulated in mammals before birth (Yang et al., 2015). This temporal pattern of expression is reminiscent to what is observed in NBs during Drosophila larval stages and suggests that the growth dynamic of fetal NSCs in mammals and larval NBs are controlled by evolutionary conserved gene networks. However, whether an analogous temporal transcription factor series in mammals similarly regulates Imp1 and Lin28a/b remains to be demonstrated.

We noticed that loss of Chinmo in temporally blocked NBs does not induce the silencing of Imp. In contrast, Chinmo is necessary for Imp maintenance in tumors. Thus, chinmo and Imp are not subordinated to the same regulatory mechanisms whether in a developmental or in a tumorigenic context. This indicates that regulatory mechanisms upstream of chinmo and Imp may be different in normal NBs (the temporal series) and in dNBs after co-option.

A NSC-encoded clock that regulates malignant susceptibility during early development

We have shown that progression throughout the NB-encoded series of temporal transcription factors terminates an early window of malignant susceptibility in the developing CNS around the beginning of the L3 stage. GMCs born during this early developmental window can generate malignant tumors upon loss of Pros. In contrast, GMCs born after the early window generate benign tumors that either completely differentiate during metamorphosis, demonstrating sensitivity to the growth-terminating cues operating in pupae, or persist in adults but fail to consistently grow, demonstrating a limited growth potential. Blocking progression of the temporal patterning system from early larval stages extends the window of susceptibility and late-born GMCs remain prone to malignant transformation, up to (and possibly beyond) metamorphosis. Our clonal analysis indicates that this window of malignant susceptibility correspond to the temporal window of expression of Chinmo and Imp. All together, our data strongly suggest that it is the presence of an activated Chinmo/Imp module in the cell (GMC) of origin that confers malignant potential. Thus, the temporal patterning regulates malignant susceptibility, at least partly, through the temporal control of Chinmo and Imp in newly-born GMCs during neurogenesis. Whether embryonic GMCs are prone to malignant transformation, like early larval GMCs, remains unclear. We could not in our various assays limit the loss of Pros to embryonically-born GMCs. This question therefore requires further investigation.

Our work reveals a model for the rapid malignant progression of tumors with an early developmental origin. First, inactivation of genes that govern the terminal differentiation of intermediate progenitors or immature neurons triggers exponential NSC amplification. Second, if occurring at an early developmental stage, this dedifferentiation process interferes with the NSC-encoded temporal program that normally limits mitotic potential by silencing genes like Chinmo, Imp and Lin-28 in Drosophila. As a result, Chinmo, Imp and Lin-28 (or their analogs in humans) are co-opted in dedifferentiated cells to unleash an early mode of growth that is resistant to differentiation cues during late development and sufficient to sustain unlimited NSC amplification and malignant progression. In contrast to tumors initiated during adulthood, the cells of origin (CIL+ GMCs in the case of pros-/- tumors) already express the early oncogenic modules that are sufficient to sustain rapid growth. Consequently, early-induced tumors do not need to accumulate novel mutations to progress to malignancy. In contrast, later-born neural cells that have already silenced proto-oncogenic, modules may require the accumulation of more genetic and epigenetic alterations for the reestablishment of oncogenic combinations causing malignancy. All together, our data uncovers the developmental program regulating the malignant susceptibility of neural cells in Drosophila, and provides a model that may help to unveil the molecular basis underlying the rapid malignant growth of neural tumors with early developmental origins.

Deciphering temporal patterning in neural progenitors to understand human tumors with early developmental origins

A recent study in mice has shown that inactivation of Smarcb1 can most efficiently cause tumors resembling atypical teratoid/rhabdoid tumours (AT/RTs), an agressive pediatric CNS cancer, when induced during an early window of pre-natal development (E6 to E10) (Han et al., 2016). In human, the embryonic/fetal origin of tumor cells is also suspected for a number of other pediatric neural cancers such as medulloblastoma in the cerebellum, retinoblastoma in the eye, and neuroblastoma in the sympathetic nervous system (Marshall et al., 2014). Such tumors are typically composed of cells with immature characteristics, referred to as embryonal (Marshall et al., 2014), and they usually carry few genetic alterations (Vogelstein et al., 2013). However, the mechanisms underlying their rapid malignant transformation remains largely unsolved.

We have demonstrated that the ability of human LIN28A/B to promote Chinmo expression in tumors is conserved in Drosophila, indicating that some regulatory aspects of the Chinmo/Imp/Lin-28 oncogenic module are likely to be evolutionary conserved. Interestingly, a recent survey of the scientific literature has revealed that LIN28A/B genes are much more frequently expressed in pediatric cancers than adult ones (Carmel-Gross et al., 2016), a feature often associated with poor prognosis (Molenaar et al., 2012; Zhou et al., 2013). Human IMPs/IGF2BPs proteins have been less extensively investigated but are expressed in neuroblastoma and other cancers and are also associated with a poor outcome (Bell et al., 2013; 2015). MYCN is a transcription factor of the MYC family, that like Chinmo in Drosophila, is expressed during early neurogenesis and promotes ribosome biogenesis and protein synthesis (Boon et al., 2001; Knoepfler et al., 2002; Wiese et al., 2013). Interestingly, it is known to be up-regulated in many pediatric cancers of neural origin (Huang and Weiss, 2013; Swartling et al., 2010; Theriault et al., 2014), and is positively regulated by LIN28 and IMPs/IGF2BPs in neuroblastoma (Bell et al., 2015; Cotterman and Knoepfler, 2009; Molenaar et al., 2012). Thus, Chinmo/Imp/Lin-28 in insect may compose an ancestral oncogenic module with similar functions and regulatory interactions as mammalian MYCN/IMP/LIN28 during early neural development and tumorigenesis.

Whether the temporal expression pattern of such modules, or oncofetal genes in general, delineates windows of malignant susceptibility in mammals is not clear. Interestingly, retinoblastoma is caused by the loss of the Retinoblastoma (Rb) protein that triggers dedifferentiation of photoreceptor cone cells (Xu et al., 2014). Cone cells are among the earliest progeny to be generated by retinal progenitors (from E12 to E16 in mice) and their birth-order is dictated by a series of sequentially expressed temporal transcription factors (Mattar et al., 2015; Young, 1985). In human, maturing cone cells in the retina, but not later born photoreceptors, express high levels of MYCN. Moreover, cooption of MYCN appears instrumental for retinoblastoma tumor growth (Xu et al., 2009). Therefore, temporal patterning in retinal progenitors, as in Drosophila NBs, may dictate the malignant susceptibility of their progeny according to their birth order through the regulation of an early growth module involving MYCN. Our work suggests that deciphering temporal specification mechanisms in the different regions of the nervous system will help identify the cell types and gene networks at the origin of pediatric neural cancers.

Materials and methods

Fly culture

Request a detailed protocol

Drosophila stocks were maintained at 18°C on standard medium (8% cornmeal/8% yeast/1% agar). Sterol-free fly food was obtained by replacing classical yeast strain by a sterol-mutant erg2 knock-out strain in the medium (Katsuyama and Paro, 2013; Parkin and Burnet, 1986).

Image processing

Request a detailed protocol

Confocal images were acquired on Zeiss LSM510 and Zeiss LSM780. ImageJ, FIJI and Photoshop were used to process confocal data. The area of individual tumors was measured from a z-projection of the entire tissue.

Statistical analysis

Request a detailed protocol

For each experiment, at least 3 biological replicates were peformed.

Biological replicates are defined as replicates of the same experiment with flies being generated by different parent flies.

For all experiments, we performed a Mann-Whitney test for statistical analysis, except for Figure 7D and Figure 3—figure supplement 2 where a Fisher’s exact test was used.

No data were excluded.

Statistical test were performed with the online BiostaTGV (http://marne.u707.jussieu.fr/biostatgv/).

Results are presented as dot plots, also depicting the median in red and a boxplot in the background (Whisker mode : 1.5IQR).

The sample size (n), the mean (m), the standard error of the mean (SEM), and the p-value are reported in the Figure legends.

****: p-value ≤ 0.0001, ***: p-value ≤ 0.001, **: p-value ≤ 0.01 and *: p-value ≤ 0.05.

Fly lines

Request a detailed protocol

Experiments were performed at various temperatures as stated below. For generating MARCM clones (Lee and Luo, 1999), the following driver stocks were used:

  • FRT19A, tubP-GAL80, hs-FLP1 w; tub-GAL4, UAS-mCD8-GFP/CyOActGFP

  • elav-GAL4, UAS-mCD8-GFP, hs-FLP122; FRT40A, tubP-GAL80/CyO

  • hs-FLP122, tubGal4, UAS-GFP; tub-GAL80, FRT40A; Δlin-28

  • hs-FLP122, tubGal4, UAS-GFP; tub-GAL80 FRT80B

  • w, tub-GAL4, UAS-nlsGFP::6xmyc::NLS, hsFLP122; FRT82B, tubP-GAL80/TM6B

They were crossed with the following stocks:

  • FRT19A, Imp7/FM6 (Munro et al., 2006) (from F. Besse)

  • chinmo1, UAS-mCD8-GFP, FRT40A/CyO (Zhu et al., 2006)

  • brat11, FRT40A/CyOActGFP (from B. Bello)

  • FRT2A, Df(3L)nerfin-1159/TM6b (from L. Cheng (Froldi et al., 2015))

  • FRT82B, pros17/TM6 (from Bloomington #5458)

  • FRT82B, cas24/TM6 (Maurange et al., 2008)

  • FRT82B, pros17, cas24/TM6

  • FRT82B, svpe22/TM6 (from Bloomington #6190).

  • Δlin-28, FRT80B/TM6 (Chen et al., 2015a)

  • UAS-prosRNAi/CyOActGFP; Δlin-28, FRT80B/TM6

  • brat11, FRT40A/CyOActGFP; Dlin-28/TM6

The progeny of the above crosses were heat-shocked 1 hr at 37°C just after larval hatching and raised at 25°C.

  • FRT82B, svpe22, UAS-chinmoRNAi1/TM6 (UAS-chinmoRNAi1 from TRiP #HMS00036, Bloomington #33638)

  • UAS-ImpRNAi1; FRT82B svpe22, UAS-chinmoRNAi1/TM6 (UAS-ImpRNAi1from VDRC #20322).

The progeny of the above crosses were heat-shocked 1 hr at 37°C just after larval hatching and raised at 29°C.

  • UAS-prosRNAi; FRT82B, svpe22, Gal80ts/TM6 (UAS-prosRNAi from VDRC #101477)

The progeny of this cross were raised at 18°C, heat-shocked 1 hr at 37°C just after larval hatching, and either maintained at kept at 18°C (restrictive temperature) for the rest of development (controls) or switched at 29°C (permissive temperature) in late L3 stage or early pupae (Figure 9A).

Flip-out clones were generated using hs-FLP; Act5c>CD2>GAL4, UAS-GFP (from N. Tapon) with:

  • UAS-chinmo (Bloomington #50740)

The progeny of this cross were heat-shocked 1 hr at 37°C just after larval hatching and raised at 25°C.

  • UAS-prosRNAi UAS-chinmoRNAi1(TRiP#HMS00036, Bloomington #33638)

The progeny of this cross were heat-shocked 1 hr at 37°C during L2 stages and raised at 29°C.

The GAL4 lines used were the following:

  • nab-GAL4 (#6190 from Kyoto DGRC) is a GAL4 trap inserted into nab (CG33545) that is active in all NBs of the VNC and central brain from late embryogenesis (Maurange et al., 2008)

  • eagle-GAL4 (eg-GAL4, Bloomington #8758) is active in a small subset of NBs in the VNC and brain.

  • poxn-GAL4 (Boll and Noll, 2002) is active in 6 NBs of the VNC.

The UAS lines used were:

  • UAS-chinmo (Bloomington #50740)

  • UAST-GFP-Imp (Medioni et al., 2014)

  • UAS-prosRNAi (TRiP#JF02308,Bloomington #26745)

  • UAS-prosRNAi (VDRC #101477)

  • UAS-ImpRNAi1(VDRC #20322)

  • UAS-ImpRNAi2 (VDRC #20321)

  • UAS-chinmoRNAi1(TRiP#HMS00036, Bloomington #33638)

  • UAS-chinmoRNAi2(NIG-Fly #17156R-1)

  • UAS-lin-28/CyO (Chen et al., 2015a)

  • UAS-LIN28A (Chen et al., 2015a)

  • UAS-LIN28B (Chen et al., 2015a)

  • UAS-dicer2 (Bloomington #24650 and #24651) was used in combination with GAL4 lines in order to improve RNAi efficiency.

The lin28Δ1, {lin-28::Venus} (Lin-28-V) stock contains a genomic rescue transgene encoding a fluorescently tagged Lin-28 (Chen et al., 2015a).

GFP-Imp is the protein-trap line #G0080 (Morin et al., 2001).

The progeny of the above crosses were raised at 29°C.

poxn-GAL4 is already active in embryonic NBs (Boll and Noll, 2002). However, we could show that inhibition of embryonic GAL4, using a tub-Gal80ts transgene, does not significantly alter tumor formation demonstrating that prosRNAi expression during early larval stages is sufficient to cause malignant tumors in adults.

Immunohistochemistry

Request a detailed protocol

Dissected tissues were fixed 5 min or more in 4% formaldehyde/PBS depending on the primary antibody. Stainings were performed in 0.5% triton/PBS with antibody incubations separated by several washes. Tissues were then transferred in Vectashield (Clinisciences, France) with or without DAPI for image acquisition. Primary antibodies were: chicken anti-GFP (1:1000, Tebubio, France), mouse anti-Mira (1:50, A. Gould), guinea-pig anti-Mira (1:1000, A. Wodarz), guinea-pig anti-Asense (1:1000, J. Knoblich), rabbit anti-PH3 (1:500, Millipore, Billerica, MA), rat anti-PH3 (1:500, Abcam, UK), rat anti-Elav (1:50, DSHB, Iowa City, IA), rat anti-Chinmo (1:500, N. Sokol), rabbit anti-Castor (1:500, W. Odenwald), guinea-pig anti-Hunchback (1:500, J. Reinitz), guinea-pig anti-Kruppel (1:500, J. Reinitz), rabbit anti-Pdm (1:500, X. Yang), mouse anti-Svp (1:50, DSHB), rabbit anti-Imp (1:500, P. Macdonald), rat anti-Lin-28 (1:500, N. Sokol). Adequate combinations of secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were used to reveal expression patterns.

RNA extraction

Request a detailed protocol

Females from the driver line nab-Gal4, UAS-dicer2 were crossed to males carrying UAS-prosRNAiVDRC 2) UAS-prosRNAiVDRC; UAS-chinmoRNAiTRiPand UAS-prosRNAiVDRC; UAS-chinmo. Crosses were grown 7 days at 18°C and then switched at 29°C. Late L3 VNCs were dissected in cold PBS 3 days after the 29°C switch, during 30 min dissection rounds. Dissected VNCs were put in 500μL cold Lysis Buffer (RA1 from the Total RNA Isolation kit, Macherey Nagel, Germany) supplemented with 50 μL glass beads (diameter 0.75-1mm, Roth, A554.1) and frozen in liquid nitrogen at the end of the dissection round. Sample tubes were then stored at -80°C up to RNA extraction. Biological triplicates were made for each condition with brain numbers as follows (1) n=79, n=57, n=65; (2) n= 70, n=58, n=78; (3) n=51, n=60, n=82. For the RNA extraction, dissected brains stored in liquid nitrogen were thawed on ice. 10 μL TCEP were added to each tube following by 40s vortex. RNA extraction was then performed following the Total RNA Isolation NucleoSpin RNA XS protocol (Macherey Nagel). RNA quality and quantity were checked by running samples on an Experion RNA HighSens Chip (Biorad, 700–7105, Hercules, CA) and send to the Montpellier Genomix platform for RNA sequencing.

Library preparation and sequencing

Request a detailed protocol

Libraries were constructed using the Truseq stranded mRNA sample prep kit (Illumina, ref.RS-122-2101, San Diego, CA) according to the manufacturer instructions. Briefly, poly-A RNAs were purified using oligo-d(T) magnetic beads from 300ng of total RNA. The poly-A+ RNAs were fragmented and reverse transcribed using random hexamers, Super Script II (Life Technologies, ref. 18064–014, Waltham, MA) and Actinomycin D. During the second strand generation step, dUTP substitued dTTP. This prevents the second strand to be used as a matrix during the final PCR amplification. Double stranded cDNAs were adenylated at their 3' ends before ligation was performed using Illumia's indexed adapters. Ligated cDNAs were amplified following 15 cycles PCR and PCR products were purified using AMPure XP Beads (Beckman Coulter Genomics, ref.A63881, Brea, CA). Libraries were validated using a DNA1000 chip (Agilent, ref. 5067–1504, Santa Clara, CA) on a Agilent Bioanalyzer and quantified using the KAPA Library quantification kit (Clinisciences, ref. KK4824). Four libraries were pooled in equimolar amounts per lane and sequencing was performed on an HiSeq2000 using the single read protocol (50nt).

RNA-Seq data analysis

Request a detailed protocol

Image analysis and base calling were performed using the HiSeq Control Software and Real-Time Analysis component provided by Illumina. The quality of the data was assessed using FastQC from the Babraham Institute and the Illumina software SAV (Sequence Analysis Viewer). Demultiplexing was performed using Illumina's sequencing analysis software (CASAVA 1.8.2). A splice junction mapper, TopHat 2.0.9 (Kim et al., 2013) (using Bowtie 2.1.0 [Langmead and Salzberg, 2012]), was used to align RNA-Seq reads to the Drosophila melanogaster genome (UCSC dm3) with a set of gene model annotations (genes.gtf downloaded from UCSC on March 6 2013). Final read alignments having more than 3 mismatches were discarded. Then, the gene counting was performed using HTSeq count 0.5.3p9 (union mode) (Anders et al., 2014). The data is from a strand-specific assay, the read has to be mapped to the opposite strand of the gene. Before statistical analysis, genes with less than 15 reads (cumulating all the analyzed samples) were filtered and thus removed. Differentially expressed genes were identified using the Bioconductor (Gentleman et al., 2004) package DESeq (Anders and Huber, 2010) 1.14.0. Data were normalized using the DESeq normalization method. Genes with adjusted p-value to less than 5% (according to the FDR method from Benjamini-Hochberg) were declared differentially expressed. To perform the functional analysis of the resulting list of genes with the Gene Ontology (GO) annotations, the topGO (Alexa et al., 2006) package from Bioconductor was used. Overrepresented GO terms were identified using Fisher's exact test with the weight method. As confidence threshold we used a p-value of 1%. To realize this analysis the differentially expressed genes were compared with those of all known genes present in the annotation. The GO categories were found in the Org.Dm.eg.db package (Carlson) based on the gene reporter EntrezGeneID. Gene Ontology and Kegg pathway analysis were performed using Flymine (Lyne et al., 2007). Raw RNA-seq data are available in the Gene Expression omnibus database (accession number: GSE64405).

Transplantation experiments

Request a detailed protocol

Transplantations of nab>GFP (UAS-GFP/+; nab-GAL4, UAS-dcr2/+), nab>prosRNAi (UAS-GFP/UAS-prosRNAi; nab-GAL4, UAS-dcr2/+), nab>prosRNAi; chinmoRNAi (UAS-GFP/UAS-prosRNAi; nab-GAL4, UAS-dcr2/UAS-chinmoRNAi), and nab>chinmo (UAS-GFP; nab-GAL4, UAS-dcr2/UAS-chinmo) VNCs and brains have been performed in yw females according to (Rossi and Gonzalez, 2015).

Data availability

The following data sets were generated

References

  15. Software
    1. Carlson M
    (2016)
    M. org.Dm.eg.db: Genome wide annotation for Fly, version R package version 3.2.3
    M. org.Dm.eg.db: Genome wide annotation for Fly.
    1. Huang M
    2. Weiss WA
    (2013) Neuroblastoma and MYCN
    Cold Spring Harbor Perspectives in Medicine 3:a014415.
    https://doi.org/10.1101/cshperspect.a014415

Decision letter

  1. Hugo J Bellen
    Reviewing Editor; Howard Hughes Medical Institute, Baylor College of Medicine, United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled "The temporal patterning system governs the malignant susceptibility of neural progeny during Drosophila development" for consideration by eLife. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor (Hugo Bellen) and K VijayRaghavan as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Early neural development is tightly controlled by a series of transcription factors that are expressed in a temporal fashion. In this study, the authors test the hypothesis that malignant transformation of neural progenitor cells occurs by disrupting the regulation of the temporal pattern of transcription factors that drive neuronal development. The authors find that early stage postembryonic neural progenitor cells, but not late stage neural progenitor cells, are prone to malignant transformation. Moreover, the authors present data that support a conserved role for Chinmo, Lin-28 and Imp for competency of progenitor cells to undergo malignant transformation. This is a novel and elegant study of broad interest, but there is room for improvement. The results are somewhat obscured by the fact that the paper is rather long and the genetics quite complex. The manuscript would benefit from shortening and bringing out the key results more clearly.

Main issues

The Abstract/Introduction/Discussion focuses on fetal origins of human pediatric neural tumors. However, the Drosophila data presented is mainly from postembryonic larval neuroblasts (NBs) and impressive adult dNB tumors, but not embryonic NBs. Drosophila embryonic and larval NBs are not equivalent. Thus, the data presented are not necessarily applicable to tumors of fetal origin. The manuscript should be re-written to de-emphasize the fetal connection. This would not undercut their conclusions.

The timing of MARCM clone induction should be included in the figure legends in Figure 1 supplements and Figure 2 and associated main text – this is important to the authors' conclusion that early-stage larval NBs are transformation competent.

The presentation of cancer stem cells (CSCs) in the manuscript is problematic, and gives specialists in CSC biology the impression that the authors do not understand the CSC hypothesis. A CSC is not a tumor cell derived from a tissue-specific stem cell. CSCs are functionally defined by their ability to recapitulate tumors in serial transplantation and limiting dilution assays. However, the authors do not present data that their Chinmo+ cells can recapitulate tumors upon serial transplantation (and they could do this). The issue of how their data address the CSC hypothesis is best left for the Discussion, in which they can introduce and define CSCs and compare/contrast human CSCs with their Drosophila tumor models, and use of the term "CSC" in the Results section should be replaced with the term "dNB" or "CIL".

The authors make a point that Chinmo- cells occur in their adult pros- tumors. These Chinmo- cells may be semi-differentiated and non-tumorigenic, as the authors speculate, or they may be actively cycling NBs (transcription factors, like Dpn, are downregulated in the nucleus in M phase NBs), or something else. If the authors want to support the assertions that Chinmo- cells in their pros- tumors have limited proliferation potential and that Chinmo+ cells are analogous to CSCs, then they need to do additional experiments – staining for markers (cycle, etc.), serial transplantation, and lineage tracing to show that only the Chinmo+ component of their tumors can recapitulate tumor growth. Should they choose to back away from their assertion that Chinmo+ cells are CSCs, then resolving the biology of Chinmo- tumor cells is beyond the scope.

The authors compare their model to human neuroblastoma. In humans, neuroblastoma is not a primary CNS tumor, but is a tumor of the peripheral nervous system and/or adrenal glands derived from cells of neural crest origin. The authors should indicate that they know this. Whether the human neural crest cells and/or their transformed counterparts are homologous to the Drosophila NBs/dNBs is not known. The idea that 'neuroblastomas' are primary human brain tumors is a common misconception outside of the field of neuro-oncology. If the authors want to compare their results to data from pediatric primary CNS tumors, there are more relevant human primary brain tumors, and the Discussion should be re-written with this in mind.

Figure 7 contains too many different experiments. This figure would better support the author's conclusions if the data from the sterol-free diet were moved into a supplementary figure and if the figure included nice images of the early-L2-induced pros- clones fed on a normal diet (or are we supposed to consider the MARCM clones in Figure 1 supplements?). There should also be control stains showing Lin-28 and Imp expression at 18C as a comparison for the 29C late switch panels – this way, we can clearly see that prosRNAi induction in svp-/- cells accounts for ectopic Lin-28 and Imp expression.

Other deficits are a lack (1) of the characterization of the role of Chinmo alone (not in tumors) in NB/neural lineages and (2) data to support that Chinmo regulates imp and lin-28 in WT as well as in tumors. Could the authors also define their use of "malignant" and "benign" transformation? Do they assess metastasis?

The points described below are intended to make the authors' conclusions stronger.

1) Prior reports have shown that Chinmo is expressed in the early-born offspring of NBs (Maurange Cell 2008; Zhu Cell 2006) but in this study, Chinmo seems to be expressed in the NB itself (Figure 6). Could the authors please clarify these results in the text? Also, the first section of the Results states "Because the malignant potential of dNBs has only been assessed via transplantation experiments (Caussinus and Gonzalez, 2005), which could per se promote cancer progression, we first investigated whether dNBs induced by the loss of Prospero (Pros) acquire malignant properties when left in their natural environment. dNBs were induced in the larval VNC[…]" This set of experiments seems unnecessary as the Gonzalez lab has shown that transplantation of wild type brain tissue does not yield tumors, i.e. transplantation is not sufficient for malignancy. In addition, the loss of Prospero has previously been shown to give rise to tumors in situ. See for example, Januschke and Gonzalez' review (Oncogene. 2008 27,6994-7002) "Larval brain tissue mutant for prospero or brat develop massive malignant tumors in allograft culture (Caussinus and Gonzalez, 2005) and displays significant overgrowth in situ (Bello et al., 2006; Betschinger et al., 2006; Choksi et al., 2006; Lee et al., 2006c)".

2) The effects of loss of chinmo alone (i.e., without concomitant loss of svp or pros or brat) is not explored in this paper, and such data would really strengthen the paper.

3) Chinmo is proposed to counteract neuronal differentiation in pupae and sustain proliferation, yet prospero mutant clones in the adult contain both Chinmo positive and negative cells. Can the authors suggest how Chinmo positive cells give rise to Chinmo negative cells? Does Chinmo turn over rapidly or is there a negative regulator, which is overcome by Imp? Moreover, the authors propose that Chinmo+ dNBs fulfill criteria for cancer stem cells. Can this be demonstrated in a metastasis assay?

4) The effects of gain of chinmo alone (chinmo Flp-out clones, see Figure 3) needs better characterization and quantification (like that for pros RNAi Flp-out and brat MARCM in Figure 3).

5) In Figure 4C-D, data seems to be missing and the legend is incomplete. There are no wild-type control panels to show Mira/Chinmo/Lin-28/Imp expression in normal VNCs. The stains shown in Figure 4C-D are confusing – yellow dashed lines are shown as though clones are presented, but not explained. In the late L3 pictures, many cells outside of the yellow lines express Lin-28, Chinmo, and Imp – what are those cells?

6) The authors do not address the role of the loss of lin-28 in their tumor model. These data would be helpful and could be obtained by a mir-sponge.

7) Most of the images are from the VNC but the authors state that their results are applicable to the central brain as well. It would be helpful to clarify in the text and each figure whether the image in from VNC or central brain. It would also be helpful to ensure that there are representative images and quantification of central brain tumors.

8) A better characterization of what Chinmo does in wild-type (non-tumors) would be helpful. Does it regulate imp and lin-28 in WT or only in pros, svp, brat mutant tumors?

9) Regarding the regulation of other target genes by Imp that determine the oncogenicity of Chinmo. Is there evidence to back up this claim?

10) The relationship of Chinmo to the temporal series is not clear to me, and it would be helpful to clarify these relationships in the text.

11) The authors describe the translational effect of Lin-28 on Chinmo and Imp, "in the tumorigenic context". Why is this effect only observed in tumor conditions? What are the other factors required?

[Editors' note: further revisions were requested prior to acceptance, as described below.]

Thank you for resubmitting your work entitled "Neural stem cell-encoded temporal patterning delineates an early window of malignant susceptibility in Drosophila" for further consideration at eLife. Your revised article has been favorably evaluated by K VijayRaghavan (Senior editor), a Reviewing editor, Hugo Bellen, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below. Please make the requested textual changes and corrections as suggested by the reviewers.

Reviewer #1:

In this revised manuscript, the authors have satisfied most of the experimental issues that I raised in my original critique. However, I have two related concerns about the Discussion that arise from an inaccurate comparison with "oncogene addition" and the claim that chinmo is the functional ortholog of Nmyc. Regarding oncogene addiction, this idea was first put forth more than a decade ago (see Torti 2011 EMBO Mol Med 3, 623-636), and one key component of this theory is that when the oncogene is removed/silenced in the tumor cell, that cell dies. This is not observed when chinmo is removed from the tumors. They tumors are smaller when chinmo is removed (because they proliferate less) but there are no data to suggest that the dNb lacking chinmo dies. Therefore, their data are more consistent with chinmo being a cancer stem cell gene and not an addictive oncogene. I strongly suggest that this part of the Discussion is edited.

The last two pages of the Discussion provide a lengthy conjecture on the possibility that chinmo is a functional ortholog of Nmyc. I have strong reservations about this entire section and find it naïve. First, chinmo and Nmyc have no structural/sequence similarity and they don't share the same domain structure. So this basis for their claim is not compelling. Most of the argument is based upon the observation that many genes involved in ribosome biogenesis are upregulated in dNbs, and this serves as the tenuous link between chinmo and Nmyc. In flies, myc (dm) upregulates ribosome biogenesis by upregulating Tif-1A (Grewal Nat Cell Biol 2003). Does chinmo also upregulate Tif-1A? Does chinmo upregulate myc/dm? The authors need to provide compelling data to support their argument or they need to tone down the speculation.

Reviewer #3:

Over-all the manuscript is very much improved, and the emphasis on developmental timing of transformation and the molecules that underpin transformation make this a more novel study that the previous version. Moving the comparisons to human pediatric tumors into the Discussion also vastly improved the flow and readability. The inclusion of additional experiments, particularly the transplant assay, improve the over-all quality and potential impact. Thank you to the authors.

Specific comments/suggestion for revisions are listed below:

Figure 3 – The main point of this section is to show that Chinmo is required for tumor maintenance, especially in adult stages. The authors say that in the adult stages, prosRNAi; chinmoRNAi cells have exhausted their proliferation potential, but they do not show stains or assays for proliferation to support this. Interestingly, they do show phospho-histone H3 stains of both genotypes, but only for L3 larval stages, and, at, L3, there is only a slight and not statistically significant difference in phospho-histone staining at this stage, which does not support their conclusions regarding reduced proliferative potential of prosRNAi; chinmoRNAi cells. It would be better to show phospho-histone staining of prosRNAi; chinmoRNAi cells vs. prosRNAi cells in the adult here.

Figure 4—figure supplement 2, seems to be a mix of supplementary data for Figure 3 and 4. Panels A and B are related to Figure 3 and are related to proliferation (phosho-histone staining and mitotic index of Chinmo+ vs. Chinmo- pros RNAi cells). Panels A and B should be moved out and referred somewhere in lines 190-200. Or are they mislabeled?

In the last paragraph of the subsection “Chinmo boosts protein biosynthesis and expression of the mRNA-binding proteins Imp and Lin-28”: the authors say that Figure 4C shows wild-type Imp and lin-28 staining, but I see no wild-type brain shown. I assume that they are referring to tissue surrounding the Mira-positive cells outlined in yellow in the L3 and in the insets with asterisks, which both shown cells in poxn>prosRNAi VNCs. These are mutant brains, not wild-type brains, and are not adequate wild-type controls. No elav staining is shown to indicate that Imp-Lin-28-positive cells outside of the yellow lines are actually neurons – these cells have large nuclei consistent with an NB-like identity, rather than a neuron-identity. They should show true wild-type control NBs to support their contention that Imp and lin-28 are not expressed in normal L3 NBs (also, see below re expression in L2).

In the subsection “Lin-28 boosts Chinmo expression within tumors”: The authors state that overexpression of lin-28 in pros- cells increases the number of Chinmo+ Imp+ cells, but they only quantify the Chinmo+ cells in Figure 6. They show an increased number of Imp+ Chinmo+ cells in a single representative sample in Figure 6—figure supplement 2, but there is no quantification. Quantification of the effect on Imp+ cells is needed to support the stated conclusion.

In the subsection “Lin-28 boosts Chinmo expression within tumors”: the authors mention that their results regarding lin-28 in dNBs are consistent with publications regarding lin-28 function in human neuroblastoma. The way the sentence is worded gives the reader the impression that the authors consider human neuroblastoma evolutionarily homologous to their fly tumors, but they are not, and the authors do not otherwise show that they are. The authors are advised to remove this assertion.

In the subsection “The temporal series silences chinmo, Imp and lin-28 in late NBs to limit their mitotic potential”: Here the authors state that Imp and Lin-28 are co-expressed with Chinmo is "early larval NBs and their progeny in the VNC," but they do not specifically state at which stage. This is confusing because in previous lines (subsection “Chinmo boosts protein biosynthesis and expression of the mRNA-binding proteins Imp and Lin-28”, last paragraph) they state that in L3 larval, Imp and Lin-28 are not expressed in NBs. The subsection “The temporal series silences chinmo, Imp and lin-28 in late NBs to limit their mitotic potential” should be revised to more accurately state that timing of Imp and Lin-28 expression in L2 NBs and not in late L3 in normal brains. The way the data in the last paragraph of the subsection “Chinmo boosts protein biosynthesis and expression of the mRNA-binding proteins Imp and Lin-28” are presented leaves the reader with the impression that Imp and Lin-28 expression are ectopically acquired in the L3 and adult tumor cells, rather than inappropriately maintained past L2. Also, if the timing of Imp and lin-28 expression in wild-type is so crucial to understanding the tumor phenotypes, then proper wild-type L3 control stains should be presented as mentioned above.

Figure 8 – Note more clearly in main text or figure legend that, in D, the GFP and Mira staining show widespread proliferative dNBs in the CNS – the image show in the L1/L2 panels is low magnification and the green and red staining appear to be so widespread that they look like background. Or maybe a higher magnificent image of part of the brain could be shown?

In the first paragraph of the subsection “An archaic model for human neural tumors with early developmental origins?”: It is not an established fact that medulloblastomas (MB), PNETs, and other neural tumors arise in the fetal or embryonic stages. Plenty of data exist to contradict this assertion, and the citations the authors use do not support this assertion (Kaatch is an epidemology review, and Vogelstein is a review about cancer genomics in general). For example, several experimental mouse models of MB show that tumors can arise post-natally, and the peak ages of incidence for MB is 3-5 and 8-9 years of age (diagnoses of children under 1 year of age are uncommon). The origins of these tumors is very much an active area of investigation. The similarities between the tumor cells and fetal/embryonic stem cells should not be construed to mean that these tumors therefore arise from fetal/embryonic cell types. Indeed, the term "embryonal" is not really meant to refer to these tumors' origins, but rather is a pathology term that refers to their common histological and immunohistochemical features: cells within these tumors show specific similarities to each other and to immature cells in their tissues of origin. Again, the authors misconstrue medical terminology and basic science terminology. This section of the Discussion should be re-written to de-emphasize that such tumors obligately arise from embryonic/fetal stages, and should be written to be more broadly inclusive of childhood tumors, which are thought to arise both pre- and post-natally.

An appropriate citation is:

Childhood Central Nervous System Embryonal Tumors Treatment (PDQ)

Health Professional Version. PDQ Pediatric Treatment Editorial Board. March 16, 2016.

https://doi.org/10.7554/eLife.13463.039

Author response

Summary:

Early neural development is tightly controlled by a series of transcription factors that are expressed in a temporal fashion. In this study, the authors test the hypothesis that malignant transformation of neural progenitor cells occurs by disrupting the regulation of the temporal pattern of transcription factors that drive neuronal development. The authors find that early stage postembryonic neural progenitor cells, but not late stage neural progenitor cells, are prone to malignant transformation. Moreover, the authors present data that support a conserved role for Chinmo, Lin-28 and Imp for competency of progenitor cells to undergo malignant transformation. This is a novel and elegant study of broad interest, but there is room for improvement. The results are somewhat obscured by the fact that the paper is rather long and the genetics quite complex. The manuscript would benefit from shortening and bringing out the key results more clearly.

In line with the recommendation of the editor and reviewers, we have tried to shorten the manuscript while highlighting and reinforcing our key results. This has involved the addition of several new experiments that can be seen in Figure 2—figure supplement 1(stainings of tumors with anti-Pdm and anti-Svp), Figure 3D (Transplantation experiments), Figure 6—figure supplement 1 (role of Lin-28 in tumor growth), and Figure 7 (role of Chinmo in NBs during development). We have also modified several figures, adding additional quantifications and controls to satisfy reviewers’ requests (e.g. Figure 1D, Figure 1—figure supplement 2, Figure 2D, Figure 3—figure supplement 2, Figure 4—figure supplement 2B) and decided to remove several experiments (ex-Figure 3H and ex-Figure 5D) that we think were not essential to convey the main findings and were sometimes shifting the focus towards issues beyond the scope of the study. We believe this current manuscript represents a clarified and improved version.

The Abstract/Introduction/Discussion focuses on fetal origins of human pediatric neural tumors. However, the Drosophila data presented is mainly from postembryonic larval neuroblasts (NBs) and impressive adult dNB tumors, but not embryonic NBs. Drosophila embryonic and larval NBs are not equivalent. Thus, the data presented are not necessarily applicable to tumors of fetal origin. The manuscript should be re-written to de-emphasize the fetal connection. This would not undercut their conclusions.

First, we would like to clarify that adult malignant tumors in our manuscript have always been induced during an early window of larval development (from L1 to early L3). Therefore, they are not “adult” tumors but “developmental” tumors. In order to clarify this point in the text, we have replaced the term “adult tumors” by more explicit terms, such as “tumors that persist in adults”.

Concerning the question of the possible correspondence of embryonic and larval stages in insects to fetal stages in mammals, it is actually difficult to determine which Drosophila developmental stages resemble more fetal stages in mammals. Interestingly, in the mouse cortex, both Imp1/Igf2bp1 and Lin28a are highly expressed in early fetal neural stem cells but their expression decreases from E14 and to be silenced at birth (Balzer et al. 2010, Development; Nishino et al. 2013, eLife; Yang et al. 2015, Development). This is reminiscent to our observation that Imp and Lin-28 are highly expressed in early larval NBs and are silenced during L3 stages. Therefore, in terms of neural development, the larval period during which Imp and Lin-28 are expressed in NBs could be equivalent to embryonic/fetal stages in mice when Imp1 and Lin28a are expressed.

Moreover, late stages of embryogenesis and early fetal stages in mammals are typically characterized by high rates of cell proliferation and organismal growth that slow down towards birth. In Drosophila, there is no organismal growth during embryogenesis, but larval stages exhibit high rates of both cell proliferation and organismal growth (Church and Robertson 1966, Journal of Experimental Zoology; Tenessen and Thummel 2011, Current Biology). Precisely, body mass increases exponentially from late L1 to mid-L3 stages, when larvae are subjected to ecdysone pulses in order to start metamorphosis. Therefore, the first 2/3 of larval stages in Drosophila are very similar to late embryonic and fetal stages in mammals in that they constitute an early period of development with very high levels of cell proliferation and growth and low levels of differentiation.

In our opinion, these data argue that the regulation of tissue growth during early larval stages in Drosophila and late embryonic/early fetal stages in mammals may be very similar, in particular concerning the nervous system. We therefore think it is important to keep the analogy between this model of neural tumor in Drosophila and tumors with early developmental (embryonic or fetal) origins in humans, like embryonal neural tumors. To clarify this issue, we have now emphasized the similarities between larval NBs in Drosophila and fetal NSCs in mammals in the Discussion (subsection “Temporal regulation of NSC mitotic potential during development”, second paragraph), and we have removed the term “fetal” from the Abstract and tried to tone down this aspect in the Introduction.

The timing of MARCM clone induction should be included in the figure legends in Figure 1 supplements and Figure 2 and associated main text – this is important to the authors' conclusion that early-stage larval NBs are transformation competent.

We have now added the timing of MARCM clone induction (L1/L2 or mid-L3) in all appropriate figures and in the associated main text.

The presentation of cancer stem cells (CSCs) in the manuscript is problematic, and gives specialists in CSC biology the impression that the authors do not understand the CSC hypothesis. A CSC is not a tumor cell derived from a tissue-specific stem cell. CSCs are functionally defined by their ability to recapitulate tumors in serial transplantation and limiting dilution assays. However, the authors do not present data that their Chinmo+ cells can recapitulate tumors upon serial transplantation (and they could do this). The issue of how their data address the CSC hypothesis is best left for the Discussion, in which they can introduce and define CSCs and compare/contrast human CSCs with their Drosophila tumor models, and use of the term "CSC" in the Results section should be replaced with the term "dNB" or "CIL".

We thank the reviewers for alerting us on this important point and agree that the work here is too preliminary to unambiguously demonstrate that Chinmo+ dNBs are CSCs. There is theoretically the possibility that Chinmo+ dNBs act as a transient amplifying population of cells necessary for tumor growth but with a limited self-renewal potential, while the CSC population would be a rare population of Chinmo- cells with low mitotic activity. As suggested by the reviewer, we replaced the term “CSC” by the term “Chinmo+ dNBs” throughout the Results section, and discuss the possibility of CSCs in the Discussion (subsection “An oncogenic module defining growth-sustaining cells in neural tumors with early developmental origins”, last paragraph).

The authors make a point that Chinmo- cells occur in their adult pros- tumors. These Chinmo- cells may be semi-differentiated and non-tumorigenic, as the authors speculate, or they may be actively cycling NBs (transcription factors, like Dpn, are downregulated in the nucleus in M phase NBs), or something else. If the authors want to support the assertions that Chinmo- cells in their pros- tumors have limited proliferation potential and that Chinmo+ cells are analogous to CSCs, then they need to do additional experiments – staining for markers (cycle, etc.), serial transplantation, and lineage tracing to show that only the Chinmo+ component of their tumors can recapitulate tumor growth. Should they choose to back away from their assertion that Chinmo+ cells are CSCs, then resolving the biology of Chinmo- tumor cells is beyond the scope.

We have now confirmed that at least a large fraction of Chinmo- cells in tumors are actively cycling dNBs by showing a co-staining of PH3 (to show mitotic activity), Miranda (to show NB identity), and Chinmo (new Figure 4—figure supplement 2A). Our quantitative analysis shows that the fraction of mitotic Chinmo- NBs is lower than for Chinmo+ NBs (Figure 4—figure supplement 2B). This can be explained by slow cycling chinmo- NBs, or by the existence of a sub-population of chinmo- NBs that have undergone cell-cycle exit. We agree that we cannot unambiguously demonstrate that Chinmo+ cells are CSCs and that Chinmo- cells have a limited proliferation potential without performing additional lineage tracing and transplantation experiments. Therefore, we have indeed chosen to back away from our initial assertion and now only discuss these possibilities in the Discussion (subsection “An oncogenic module defining growth-sustaining cells in neural tumors with early developmental origins”, last paragraph). These questions will be thoroughly addressed in another study. We have instead chosen to reinforce our finding that Chinmo is required and sufficient for sustained tumor growth by performing transplantation experiments (new Figure 3D).

The authors compare their model to human neuroblastoma. In humans, neuroblastoma is not a primary CNS tumor, but is a tumor of the peripheral nervous system and/or adrenal glands derived from cells of neural crest origin. The authors should indicate that they know this. Whether the human neural crest cells and/or their transformed counterparts are homologous to the Drosophila NBs/dNBs is not known. The idea that 'neuroblastomas' are primary human brain tumors is a common misconception outside of the field of neuro-oncology. If the authors want to compare their results to data from pediatric primary CNS tumors, there are more relevant human primary brain tumors, and the Discussion should be re-written with this in mind.

The reason we initially emphasized the resemblance of neuroblastoma with Drosophila NB tumors is because of the expression and role of Lin28 and Imp that has essentially been described in this kind of pediatric cancer. Whether Drosophila NB tumors, as an archaic model, resemble more pediatric primary CNS or PNS tumors remains to be clearly investigated. We have now modified the Discussion and added the corresponding tissue of origin for each tumor type discussed.

Figure 7 contains too many different experiments. This figure would better support the author's conclusions if the data from the sterol-free diet were moved into a supplementary figure and if the figure included nice images of the early-L2-induced pros- clones fed on a normal diet (or are we supposed to consider the MARCM clones in Figure 1 supplements?). There should also be control stains showing Lin-28 and Imp expression at 18C as a comparison for the 29C late switch panels – this way, we can clearly see that prosRNAi induction in svp-/- cells accounts for ectopic Lin-28 and Imp expression.

We have now split ex-Figure 7 (now new Figures 8 and 9) and the text accordingly. New Figure 8 now concentrates on the different phenotypes generated by inducing tumors at early (L1/L2) or late (mid-L3) larval stages demonstrating that malignant Chinmo+ tumors can only be induced during an early window of development. The figure now contains image of early- and late- induced MARCM clones, 1 day, 3 days and 7 days after induction.

New Figure 9 now focuses on the role of the temporal transcription factor series in the regulation of this early window of malignant susceptibility. The goal of the temperature switching experiment is to demonstrate that the presence of Chinmo, Imp and Lin-28 in tumors and their ability to become malignant depend on the temporal identity of the cell of origin, and not on the developmental stage of the organism (here we block temporal progression in the svp-/- NBs without affecting developmental progression of the organism).

The 18°C control experiment aims at showing that the prosRNAi is ineffective when larvae are kept at this temperature (due to the GAL80ts-mediated repression). Therefore, tumors seen in the “late switch to 29°C” experiments are really induced by the late temperature switch, and were not preexisting at earlier stages. As shown, the prosRNAiis ineffective at 18°C, this experiment is therefore similar to inducing svp-/-MARCM clones. We have shown that these clones do retain Chinmo, Imp and Lin-28 expression when induced in L1/L2 and observed in adults (Figure 7B). Thus, we don’t think reassessing the expression of these factors in the 18°C experiment would bring novel insights. However, we have now better explained the experiments in the main text (subsection “The temporal identity of a cell determines its malignant susceptibility”) and in the Materials and methods (subsection “Fly lines”).

Other deficits are a lack (1) of the characterization of the role of Chinmo alone (not in tumors) in NB/neural lineages and (2) data to support that Chinmo regulates imp and lin-28 in WT as well as in tumors.

We have now looked more carefully at the role of Chinmo during larval neurogenesis by inducing loss-of-function clones. Our findings suggest that Chinmo is dispensable for NB mitotic activity during development since chinmo-/- clones contained the same number of cells as wt clones (new Figure 7C-F) at the end of larval stages. This finding is corroborated by the fact that chinmoRNAi, svp-/-NBs, blocked in an early temporal identity, continued to divide in adults (Figure 7G). Thus, the growth of NB lineages during development and tumorigenesis does not exhibit the same dependency on Chinmo. This reveals a tumor-specific Chinmo addiction. This point has now been added in the Results (subsection “The temporal series silences chinmo, Imp and lin-28 in late NBs to limit their mitotic potential”, first paragraph) and Discussion (subsection “Temporal regulation of NSC mitotic potential during development”).

Intriguingly, chinmoRNAi, svp-/-NBs maintained Imp expression showing that, in contrast to dNBs (Figure 4—figure supplement 1), Imp expression in NBs with an early temporal identity does not rely on Chinmo (Figure 7G). Thus, Chinmo and Imp in progenitors are not subordinated to similar cross-regulatory interactions whether in the developmental or in the tumorigenic context (subsection “Temporal regulation of NSC mitotic potential during development”, last paragraph).

However, ImpRNAi, chinmoRNAi, svp-/- NBs did not persist in adults (Figure 7G). Thus, the presence of the Chinmo/Imp module is required to sustain the mitotic activity of NBs blocked in an early temporal identity. It is therefore important that the temporal series switches off the Chinmo/Imp module during late larval stages to limit their proliferation potential and ensure that NBs become competent to undergo terminal differentiation during metamorphosis.

Could the authors also define their use of "malignant" and "benign" transformation? Do they assess metastasis?

Malignant tumors, as we define them, are the ones that resist differentiation during metamorphosis and continue growing at a fast rate in adults. This is assessed by their ability to cover the whole VNC (or brain in case of brat-/- clones) after about 5 days. We have also observed that these tumors after 5 days invade adjacent tissues, mainly by following axonal bundles emanating from the CNS (not shown). However, we have not systematically assessed this property in our assays.

In contrast, benign tumors are the ones that have a limited ability to persist in adults as they tend to be more efficiently eliminated during metamorphosis upon differentiation cues. When they persist in adults, they do not grow, or grow at a very low rate such that the VNC, or brain is never covered after 5 days.

We have tried to clarify this issue, in the Results section by adding:

“Therefore, NB tumors induced by the loss of Pros during early larval stages and maintained in their natural environment resist differentiation cues operating during metamorphosis, and invariably acquire an unlimited growth potential as well as invasive properties. As such, we define them as malignant tumors.”and “In contrast, dNBs induced by the dedifferentiation of late-born CIL-negative GMCs cannot reactivate Chinmo expression, possess a limited proliferation potential and undergo terminal differentiation during metamorphosis like wt NBs, or persist as benign, slow-growing, tumors in adults.”

The points described below are intended to make the authors' conclusions stronger.

1) Prior reports have shown that Chinmo is expressed in the early-born offspring of NBs (Maurange Cell 2008; Zhu Cell 2006) but in this study, Chinmo seems to be expressed in the NB itself (Figure 6). Could the authors please clarify these results in the text?

We have clarified this point in the text: “We then concentrated on Chinmo, a transcription factor known to label a sub-population of early-born neurons in type-I lineages in larvae (Maurange et al., 2008; Zhu et al., 2006), Figure 2A). […] Therefore, Chinmo is a marker of early temporal identity and its window of expression in NBs is terminated in early L3 by progression of the temporal transcription factor series (Figure 2H).”

Also, the first section of the Results states "Because the malignant potential of dNBs has only been assessed via transplantation experiments (Caussinus and Gonzalez, 2005), which could per se promote cancer progression, we first investigated whether dNBs induced by the loss of Prospero (Pros) acquire malignant properties when left in their natural environment. dNBs were induced in the larval VNC…" This set of experiments seems unnecessary as the Gonzalez lab has shown that transplantation of wild type brain tissue does not yield tumors, i.e. transplantation is not sufficient for malignancy. In addition, the loss of Prospero has previously been shown to give rise to tumors in situ. See for example, Januschke and Gonzalez' review (Oncogene. 2008 27,6994-7002) "Larval brain tissue mutant for prospero or brat develop massive malignant tumors in allograft culture (Caussinus and Gonzalez, 2005) and displays significant overgrowth in situ (Bello et al., 2006; Betschinger et al., 2006; Choksi et al., 2006; Lee et al., 2006c)".

In the first manuscript, it was not our intention to imply that transplantation might be sufficient for malignancy but instead that the process of transplantation, that involves cutting the tumor in pieces and injecting it in the abdominal cavity of adult flies, could favor the transformation of tumor cells (for example by favoring cell dissemination in the hemolymph and the apparition of secondary tumors at distant sites, or by activating growth pathways triggered by wounds). Therefore, the possible contribution of transplantation to malignancy remains unclear. It therefore seemed important to us to design an assay in which early developmental tumors can be precisely tracked, to investigate how their differentiating, proliferative and invasive properties may evolve over several days/weeks, throughout development (in the case of transplantation, usually larval tumors are directly transplanted in adults) and in their natural environment with no mechanic interventions.

Our assay using pox>prosRNAi tumors induced from a defined subset of 6 NBs localized in the VNC has allowed us to show that early induced tumors undergo a period of regression during metamorphosis, demonstrating that not all dNBs have the same ability to resist differentiation cues operating in pupae (resistance to differentiation is a hallmark of cancer cells). Moreover, intact tumors never stop growing (even more than three weeks after initiation) and can invade surrounding tissues in adults. Thus, the malignant potential of tumors is not triggered by transplantation, although transplantation could still accelerate the acquisition of novel cancer hallmarks. We believe that our assay nicely complement the transplantation assay in the quest to uncover the natural events that promote early phases of malignant transformation.

We have modified the text in the first paragraph of the Results section to better explain the advantages of the pox>prosRNAi assay, and have also added new transplantation experiments to support our data concerning untransplanted tumors (new Figure 3D).

2) The effects of loss of chinmo alone (i.e., without concomitant loss of svp or pros or brat) is not explored in this paper, and such data would really strengthen the paper.

We have now investigated this issue that is discussed in the last response to the Main issues.

3) Chinmo is proposed to counteract neuronal differentiation in pupae and sustain proliferation, yet prospero mutant clones in the adult contain both Chinmo positive and negative cells. Can the authors suggest how Chinmo positive cells give rise to Chinmo negative cells? Does Chinmo turn over rapidly or is there a negative regulator, which is overcome by Imp? Moreover, the authors propose that Chinmo+ dNBs fulfill criteria for cancer stem cells. Can this be demonstrated in a metastasis assay?

For the moment, we do not know how the self-renewal of Chinmo+ dNBs or their probable transition to a Chinmo- state is regulated. This is a very interesting question and is something we are actively working on. We think however that it goes beyond the scope of the current manuscript. As mentioned in response to the third and fourth Main issue, we agree that we have not formally demonstrated that Chinmo+ cells are at the top of the tumor hierarchy and therefore have removed allusions to CSCs in the Results section. We also recognize that our lineage analysis is too preliminary to support the hypothesis that Chinmo+ cells are CSCs and have therefore removed this Figure (ex Figure 3H) from the new version of the manuscript. This hypothesis is now only mentioned in the Discussion (subsection “Temporal regulation of NSC mitotic potential during development”, last paragraph).

4) The effects of gain of chinmo alone (chinmo Flp-out clones, see Figure 3) needs better characterization and quantification (like that for pros RNAi Flp-out and brat MARCM in Figure 3).

Because adult flies containing chinmo Flp-out clones die rapidly (most of them do not actually emerge from the pupa), it is not possible to quantify their growth capacity over several days as we have done from prosRNAiand brat-/- MARCM clones. In order to circumvent this issue, we have now transplanted larval CNSs with all NBs and their GMCs overexpressing chinmo (new Figure 3D). We could show that in 26% of the cases, it is sufficient to induce tumors filling the whole abdominal cavity after 7 days. This nicely supports our initial statement that Chinmo is oncogenic and sufficient to induce sustained tumorigenic growth (subsection “Chinmo promotes resistance to differentiation and is necessary to sustain tumor growth”, last paragraph).

5) In Figure 4C-D, data seems to be missing and the legend is incomplete. There are no wild-type control panels to show Mira/Chinmo/Lin-28/Imp expression in normal VNCs. The stains shown in Figure 4C-D are confusing – yellow dashed lines are shown as though clones are presented, but not explained. In the late L3 pictures, many cells outside of the yellow lines express Lin-28, Chinmo, and Imp – what are those cells?

We have now added in Figure 4C an inset depicting a normal VNC NB and its progeny in late L3 stained with Chinmo, Imp and Lin-28. Expression of Chinmo, Lin28, Imp in VNCs throughout larval development is presented in more details in Figure 7A. We have also completed the legend and explained that the cells that express Chinmo, Imp and Lin28 outside the clones in late L3 larvae are early-born neurons.

6) The authors do not address the role of the loss of lin-28 in their tumor model. These data would be helpful and could be obtained by a mir-sponge.

We have now shown, by generating brat-/- MARCM clones in a lin-28 homozygous mutant background or by generating prosRNAi lin-28-/- MARCM clones, that Lin-28 is dispensable for tumor growth and expression of Chinmo and Imp (new Figure 6—figure supplement 1). Based on our results showing that high levels of Lin-28 can enhance the levels of Chinmo and Imp in tumors (Figure 6), we have defined lin-28 as being able to boost Chinmo/Imp oncogenic module, and not as being a core component of the module (end of subsection “Lin-28 boosts Chinmo expression within tumors”).

7) Most of the images are from the VNC but the authors state that their results are applicable to the central brain as well. It would be helpful to clarify in the text and each figure whether the image in from VNC or central brain. It would also be helpful to ensure that there are representative images and quantification of central brain tumors.

The identity of the examined tissues (VNCs or brains) has been systematically added to all images. We have quantified the volume of prosRNAitumors in the brain (new Figure 3—figure supplement 2B) as well as in brat-/- tumors in the brain (Figure 6—figure supplement 1 and Figure 3G).

8) A better characterization of what Chinmo does in wild-type (non-tumors) would be helpful. Does it regulate imp and lin-28 in WT or only in pros, svp, brat mutant tumors?

See the last response to the Main issues.

9) Regarding the regulation of other target genes by Imp that determine the oncogenicity of Chinmo. Is there evidence to back up this claim?

Our evidence was that expressing Chinmo in Imp-/- clones (using the transgene that lack the 5’UTR, and therefore does not depend on Imp for its translation) does not induce NB amplification, while expressing Chinmo in wt NBs does (ex-Figure 5D in old version). Therefore, Imp must regulate other genes to promote the oncogenic activity of Chinmo. However, as advised by the editor, we have decided to remove this set of experiments, which does not bring essential information to the main messages of the study, in order to keep the study more focused.

10) The relationship of Chinmo to the temporal series is not clear to me, and it would be helpful to clarify these relationships in the text.

We had previously shown that Chinmo in neurons is downstream to the temporal series (Maurange et al. 2008, Cell). We now extent this relationship to NBs as they are retained in late NBs that are temporally blocked (as shown in svp-/- clones for example – Figure 2B) and to Imp and Lin28 (Figure 7B). We have tried to clarify this relationship in the Introduction as well as the Results section entitled: “A subset of dNBs aberrantly maintains the early transcription factor Chinmo”. More details are also given in the Results section entitled: “The temporal series silences chinmo, Imp and lin-28 in late NBs to limit their mitotic potential”.

11) The authors describe the translational effect of Lin-28 on Chinmo and Imp, "in the tumorigenic context". Why is this effect only observed in tumor conditions? What are the other factors required?

It is true that during development, mis-expression of Lin-28 and Imp is not sufficient to promote the persistence of Chinmo beyond its normal temporal window of expression. We can only speculate that there may be some repressors of Chinmo in late NBs that counteract Lin-28 activity. Moreover, as shown in Figure 4—figure supplement 3 and Figure 7G, chinmo, Imp, and probably lin-28 are not subordinated to similar cross-regulatory interactions whether in the developmental or tumorigenic context. This is probably due to the fact that the Chinmo/Imp/lin-28 module has been coopted in dNBs but the upstream regulatory mechanisms might be different than in normal NBs. However, we think that uncovering the molecular basis of this interesting question goes beyond the scope of the current manuscript.

[Editors' note: further revisions were requested prior to acceptance, as described below.]

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below. Please make the requested textual changes and corrections as suggested by the reviewers.

Reviewer #1:

In this revised manuscript, the authors have satisfied most of the experimental issues that I raised in my original critique. However, I have two related concerns about the Discussion that arise from an inaccurate comparison with "oncogene addition" and the claim that chinmo is the functional ortholog of Nmyc. Regarding oncogene addiction, this idea was first put forth more than a decade ago (see Torti 2011 EMBO Mol Med 3, 623-636), and one key component of this theory is that when the oncogene is removed/silenced in the tumor cell, that cell dies. This is not observed when chinmo is removed from the tumors. They tumors are smaller when chinmo is removed (because they proliferate less) but there are no data to suggest that the dNb lacking chinmo dies. Therefore, their data are more consistent with chinmo being a cancer stem cell gene and not an addictive oncogene. I strongly suggest that this part of the Discussion is edited.

We agree that we have not carefully investigated whether loss of Chinmo triggers enhanced apoptosis within the tumor. We have therefore removed the comparison with oncogene addiction.

The last two pages of the Discussion provide a lengthy conjecture on the possibility that chinmo is a functional ortholog of Nmyc. I have strong reservations about this entire section and find it naïve. First, chinmo and Nmyc have no structural/sequence similarity and they don't share the same domain structure. So this basis for their claim is not compelling. Most of the argument is based upon the observation that many genes involved in ribosome biogenesis are upregulated in dNbs, and this serves as the tenuous link between chinmo and Nmyc. In flies, myc (dm) upregulates ribosome biogenesis by upregulating Tif-1A (Grewal Nat Cell Biol 2003). Does chinmo also upregulate Tif-1A? Does chinmo upregulate myc/dm? The authors need to provide compelling data to support their argument or they need to tone down the speculation.

As suggested, we have toned down the speculative discussion about Chinmo being a functional analog of MYCN. Instead, we propose that Chinmo/Imp/Lin-28 in insects may compose an oncogenic module with similar functions during development and tumorigenesis as MYCN/IMP/LIN28 in mammals. This remains speculative but not completely unfounded based on recent evidences about their temporal and spatial regulation, cross-regulatory interactions and downstream transcriptional landscape.

Reviewer #3:

Specific comments/suggestion for revisions are listed below:

Figure 3 – The main point of this section is to show that Chinmo is required for tumor maintenance, especially in adult stages. The authors say that in the adult stages, prosRNAi; chinmoRNAi cells have exhausted their proliferation potential, but they do not show stains or assays for proliferation to support this. Interestingly, they do show phospho-histone H3 stains of both genotypes, but only for L3 larval stages, and, at, L3, there is only a slight and not statistically significant difference in phospho-histone staining at this stage, which does not support their conclusions regarding reduced proliferative potential of prosRNAi; chinmoRNAi cells. It would be better to show phospho-histone staining of prosRNAi; chinmoRNAi cells vs. prosRNAi cells in the adult here.

We did show that already in larvae, the mitotic rate in prosRNAi; chinmoRNAi tumors is significantly lower than in prosRNAi tumors (Figure 3—figure supplement 1G). In addition, we have now added some new results showing that the mitotic rate of dNBs is lower in flp-out prosRNAi, chinmoRNAi clones compared to prosRNAiclones, both in larvae and adults. Moreover, we find that the mitotic index of prosRNAi, chinmoRNAi clones decreases further in adults compared to larvae, while remaining constant in prosRNAiclones. Together, these new results support a progressive exhaustion of proliferation potential in tumors lacking Chinmo. This new data has now been incorporated as Figure 3D.

Figure 4—figure supplement 2, seems to be a mix of supplementary data for Figure 3 and 4. Panels A and B are related to Figure 3 and are related to proliferation (phosho-histone staining and mitotic index of Chinmo+ vs Chinmo- pros RNAi cells). Panels A and B should be moved out and referred somewhere in lines 190-200. Or are they mislabeled?

We agree with Reviewer #3 that the results for Figure 4—figure supplement 2 A-B better fits in the previous section. It nicely shows that two types of progenitors with different mitotic properties co-exist in tumors (now Figure 3—figure supplement 3). We have also added new counts that indicate the average fraction of Chinmo+ vs Chinmo- dNBs in tumors (now Figure 2—figure supplement 5). In the future, we plan to perform detailed lineage analyses in order to precisely determine the proliferation potential of each progenitor population.

In the last paragraph of the subsection “Chinmo boosts protein biosynthesis and expression of the mRNA-binding proteins Imp and Lin-28”: the authors say that Figure 4C shows wild-type Imp and lin-28 staining, but I see no wild-type brain shown. I assume that they are referring to tissue surrounding the Mira-positive cells outlined in yellow in the L3 and in the insets with asterisks, which both shown cells in poxn>prosRNAi VNCs. These are mutant brains, not wild-type brains, and are not adequate wild-type controls. No elav staining is shown to indicate that Imp-Lin-28-positive cells outside of the yellow lines are actually neurons – these cells have large nuclei consistent with an NB-like identity, rather than a neuron-identity. They should show true wild-type control NBs to support their contention that Imp and lin-28 are not expressed in normal L3 NBs (also, see below re expression in L2).

We agree that the presentation of the immunostaining data was a bit confusing. We have now modified the text and Figure 4 such that Figure 4 only describes the expression patterns of Imp and Lin-28 in tumors, and not anymore in the wild type CNS. Here we only aim at validating the transcriptomic analysis that was performed on tumors.

Description of Imp and Lin-28 expression in the wild type CNS is now restricted to Figure 7. We have added additional data (Figure 7—figure supplement 1) to show that cells, around larval NBs, co-expressing Imp and Lin-28 during development are elav+ neurons. We have also included new stainings showing that Chinmo and Lin-28 are completely silenced in the CNS past metamorphosis, while Imp perdures in some adult neurons. We hope this clarifies the issue.

In the subsection “Lin-28 boosts Chinmo expression within tumors”: The authors state that overexpression of lin-28 in pros- cells increases the number of Chinmo+ Imp+ cells, but they only quantify the Chinmo+ cells in Figure 6. They show an increased number of Imp+.Chinmo+ cells in a single representative sample in Figure 6—figure supplement 2, but there is no quantification. Quantification of the effect on Imp+ cells is needed to support the stated conclusion.

We have not, indeed, precisely quantified Imp+ dNBs in tumors over-expressing Lin-28. However, we show in Figure 6—figure supplement 2 that in such tumors, all Chinmo+ cells are also Imp+. Given that the number of Chinmo+ cells increases, this by extension implies that the number of Imp+ cells increases in proportion. We have modified the text to make our assertion clearer and propose that Lin-28 over-expression in the tumorigenic context is able to favor the self-renewing capacity of Chinmo+/Imp+ dNBs at the expense of Chinmo-/Imp- dNBs.

In the subsection “Lin-28 boosts Chinmo expression within tumors”: the authors mention that their results regarding lin-28 in dNBs are consistent with publications regarding lin-28 function in human neuroblastoma. The way the sentence is worded gives the reader the impression that the authors consider human neuroblastoma evolutionarily homologous to their fly tumors, but they are not, and the authors do not otherwise show that they are. The authors are advised to remove this assertion.

We have now removed the mention to neuroblastoma in this sentence.

In the subsection “The temporal series silences chinmo, Imp and lin-28 in late NBs to limit their mitotic potential”: Here the authors state that Imp and Lin-28 are co-expressed with Chinmo is "early larval NBs and their progeny in the VNC," but they do not specifically state at which stage. This is confusing because in previous lines (subsection “Chinmo boosts protein biosynthesis and expression of the mRNA-binding proteins Imp and Lin-28”, last paragraph) they state that in L3 larval, Imp and Lin-28 are not expressed in NBs. The subsection “The temporal series silences chinmo, Imp and lin-28 in late NBs to limit their mitotic potential” should be revised to more accurately state that timing of Imp and Lin-28 expression in L2 NBs and not in late L3 in normal brains.

The text has been modified accordingly. We have also added a Figure 7—figure supplement 1 that shows i) that Imp+ cells surrounding NBs in larvae are elav+ neurons, ii) that Lin-28 and Chinmo are respectively silenced in all CNS cells during late larval and metamorphosis respectively, while Imp persist in a vast number of neurons in the adult CNS.

The way the data in the last paragraph of the subsection “Chinmo boosts protein biosynthesis and expression of the mRNA-binding proteins Imp and Lin-28” are presented leaves the reader with the impression that Imp and Lin-28 expression are ectopically acquired in the L3 and adult tumor cells, rather than inappropriately maintained past L2.

Indeed, at this stage in the manuscript, we still don’t know whether aberrant expression of Imp, Lin28 and Chinmo in tumors is due to ectopic expression or inappropriate maintenance, this is the purpose of the last two Results sections of the manuscript to demonstrate that this is due to inappropriate maintenance (Figure 8 and Figure 9). We hope that the presentation of the data is now clearer with the modifications we have performed in Figure 4.

Also, if the timing of Imp and lin-28 expression in wild-type is so crucial to understanding the tumor phenotypes, then proper wild-type L3 control stains should be presented as mentioned above.

Done in Figure 7—figure supplement 1.

Figure 8 – Note more clearly in main text or figure legend that, in D, the GFP and Mira staining show widespread proliferative dNBs in the CNS – the image show in the L1/L2 panels is low magnification and the green and red staining appear to be so widespread that they look like background. Or maybe a higher magnificent image of part of the brain could be shown?

We have added a higher magnification that clearly shows that red and green stainings are proliferating dNBs.

In the first paragraph of the subsection “An archaic model for human neural tumors with early developmental origins?”: It is not an established fact that medulloblastomas (MB), PNETs, and other neural tumors arise in the fetal or embryonic stages. Plenty of data exist to contradict this assertion, and the citations the authors use do not support this assertion (Kaatch is an epidemology review, and Vogelstein is a review about cancer genomics in general). For example, several experimental mouse models of MB show that tumors can arise post-natally, and the peak ages of incidence for MB is 3-5 and 8-9 years of age (diagnoses of children under 1 year of age are uncommon). The origins of these tumors is very much an active area of investigation. The similarities between the tumor cells and fetal/embryonic stem cells should not be construed to mean that these tumors therefore arise from fetal/embryonic cell types. Indeed, the term "embryonal" is not really meant to refer to these tumors' origins, but rather is a pathology term that refers to their common histological and immunohistochemical features: cells within these tumors show specific similarities to each other and to immature cells in their tissues of origin. Again, the authors misconstrue medical terminology and basic science terminology. This section of the Discussion should be re-written to de-emphasize that such tumors obligately arise from embryonic/fetal stages, and should be written to be more broadly inclusive of childhood tumors, which are thought to arise both pre- and post-natally.

An appropriate citation is:

Childhood Central Nervous System Embryonal Tumors Treatment (PDQ)

Health Professional Version. PDQ Pediatric Treatment Editorial Board. March 16, 2016.

We have now corrected the misuse of the term “embryonal”, and mention the fact that the embryonic/fetal origin of tumors is only suspected for a number of pediatric cancers. We also added a recent reference showing that in mice, Smarcb1 loss can only induce AT/RTs if induced during a restricted window of embryonic development (Han et al. 2016). Because our study involves genes like Lin-28 and Imp that are mainly expressed during embryonic/fetal stages in mammals, emphasizing these types of cancers seems pertinent to us. But although, pediatric cancers appear to be initiated during specific windows of development associated with high proliferation, we agree that depending on the tissue, it may not always be restricted to embryonic/fetal stages.

https://doi.org/10.7554/eLife.13463.040

Article and author information

Author details

  1. Karine Narbonne-Reveau

    Aix Marseille Univ, CNRS, IBDM, Marseille, France
    Contribution
    KN-R, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Contributed equally with
    Elodie Lanet and Caroline Dillard
    Competing interests
    The authors declare that no competing interests exist.

  2. Elodie Lanet

    Aix Marseille Univ, CNRS, IBDM, Marseille, France
    Contribution
    EL, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Contributed equally with
    Karine Narbonne-Reveau and Caroline Dillard
    Competing interests
    The authors declare that no competing interests exist.

  3. Caroline Dillard

    Aix Marseille Univ, CNRS, IBDM, Marseille, France
    Contribution
    CD, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    Contributed equally with
    Karine Narbonne-Reveau and Elodie Lanet
    Competing interests
    The authors declare that no competing interests exist.

  4. Sophie Foppolo

    Aix Marseille Univ, CNRS, IBDM, Marseille, France
    Contribution
    SF, Acquisition of data, Analysis and interpretation of data
    Competing interests
    The authors declare that no competing interests exist.

  5. Ching-Huan Chen

    Department of Biology, Indiana University, Bloomington, United States
    Contribution
    C-HC, Contributed unpublished essential data or reagents
    Competing interests
    The authors declare that no competing interests exist.

  6. Hugues Parrinello

    MGX-Montpellier GenomiX, Institut de Génomique Fonctionnelle, Montpellier, France
    Contribution
    HP, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  7. Stéphanie Rialle

    MGX-Montpellier GenomiX, Institut de Génomique Fonctionnelle, Montpellier, France
    Contribution
    SR, Acquisition of data
    Competing interests
    The authors declare that no competing interests exist.

  8. Nicholas S Sokol

    Department of Biology, Indiana University, Bloomington, United States
    Contribution
    NSS, Drafting or revising the article, Contributed unpublished essential data or reagents
    Competing interests
    The authors declare that no competing interests exist.

  9. Cédric Maurange

    Aix Marseille Univ, CNRS, IBDM, Marseille, France
    Contribution
    CM, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article
    For correspondence
    cedric.maurange@univ-amu.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8931-1419

Funding

Centre National de la Recherche Scientifique

  • Cédric Maurange

Fondation ARC pour la Recherche sur le Cancer (SFI20101201787)

  • Cédric Maurange

National Institutes of Health (R21OD019916)

  • Nicholas S Sokol

Fondation ARC pour la Recherche sur le Cancer

  • Elodie Lanet

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We are grateful to EA Bach, B Bello, F Besse, L Cheng, C Doe, A Gould, J Knoblich, T Lee, P Macdonald, M Noll, W Odenwald, G Struhl, A Wodarz, X Yang and C Yu for flies and antibodies, and R Paro for the erg2 yeast strain. We also acknowledge the Bloomington Drosophila Stock Center (NIH P40OD018537), the Vienna Drosophila RNAi Center (VDRC), TRiP at Harvard Medical School (NIH/NIGMS R01-GM084947), Kyoto DGRC and NIG-Fly Stock Centers, and the Developmental Studies Hybridoma Bank (DSHB) for monoclonal antibodies. We thank France-BioImaging/PICsL infrastructure (ANR-10-INSB-04-01). We thank C Bertet, H Cremer, P Durbec and B Thompson for critical reading of the manuscript.

Reviewing Editor

  1. Hugo J Bellen, Howard Hughes Medical Institute, Baylor College of Medicine, United States

Version history

  1. Received: December 1, 2015
  2. Accepted: May 26, 2016
  3. Version of Record published: June 14, 2016 (version 1)
  4. Version of Record updated: July 4, 2016 (version 2)

Copyright

© 2016, Narbonne-Reveau et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,241
    Page views
  • 731
    Downloads
  • 51
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Karine Narbonne-Reveau
  2. Elodie Lanet
  3. Caroline Dillard
  4. Sophie Foppolo
  5. Ching-Huan Chen
  6. Hugues Parrinello
  7. Stéphanie Rialle
  8. Nicholas S Sokol
  9. Cédric Maurange
(2016)
Neural stem cell-encoded temporal patterning delineates an early window of malignant susceptibility in Drosophila
eLife 5:e13463.
https://doi.org/10.7554/eLife.13463

Categories and tags

Research organism

Further reading

    1. Cancer Biology
    2. Developmental Biology

    Coopted temporal patterning governs cellular hierarchy, heterogeneity and metabolism in Drosophila neuroblast tumors

    Sara Genovese, Raphaël Clément ... Cédric Maurange
    Research Advance Updated

    It is still unclear what drives progression of childhood tumors. During Drosophila larval development, asymmetrically-dividing neural stem cells, called neuroblasts, progress through an intrinsic temporal patterning program that ensures cessation of divisions before adulthood. We previously showed that temporal patterning also delineates an early developmental window during which neuroblasts are susceptible to tumor initiation (Narbonne-Reveau et al., 2016). Using single-cell transcriptomics, clonal analysis and numerical modeling, we now identify a network of twenty larval temporal patterning genes that are redeployed within neuroblast tumors to trigger a robust hierarchical division scheme that perpetuates growth while inducing predictable cell heterogeneity. Along the hierarchy, temporal patterning genes define a differentiation trajectory that regulates glucose metabolism genes to determine the proliferative properties of tumor cells. Thus, partial redeployment of the temporal patterning program encoded in the cell of origin may govern the hierarchy, heterogeneity and growth properties of neural tumors with a developmental origin.

    1. Cancer Biology
    2. Computational and Systems Biology

    Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records

    Jessica Xin Hjaltelin, Sif Ingibergsdóttir Novitski ... Søren Brunak
    Research Article

    Pancreatic cancer is one of the deadliest cancer types with poor treatment options. Better detection of early symptoms and relevant disease correlations could improve pancreatic cancer prognosis. In this retrospective study, we used symptom and disease codes (ICD-10) from the Danish National Patient Registry (NPR) encompassing 6.9 million patients from 1994 to 2018,, of whom 23,592 were diagnosed with pancreatic cancer. The Danish cancer registry included 18,523 of these patients. To complement and compare the registry diagnosis codes with deeper clinical data, we used a text mining approach to extract symptoms from free text clinical notes in electronic health records (3078 pancreatic cancer patients and 30,780 controls). We used both data sources to generate and compare symptom disease trajectories to uncover temporal patterns of symptoms prior to pancreatic cancer diagnosis for the same patients. We show that the text mining of the clinical notes was able to complement the registry-based symptoms by capturing more symptoms prior to pancreatic cancer diagnosis. For example, ‘Blood pressure reading without diagnosis’, ‘Abnormalities of heartbeat’, and ‘Intestinal obstruction’ were not found for the registry-based analysis. Chaining symptoms together in trajectories identified two groups of patients with lower median survival (<90 days) following the trajectories ‘Cough→Jaundice→Intestinal obstruction’ and ‘Pain→Jaundice→Abnormal results of function studies’. These results provide a comprehensive comparison of the two types of pancreatic cancer symptom trajectories, which in combination can leverage the full potential of the health data and ultimately provide a fuller picture for detection of early risk factors for pancreatic cancer.

    1. Cancer Biology

    Disseminating cells in human oral tumours possess an EMT cancer stem cell marker profile that is predictive of metastasis in image-based machine learning

    Gehad Youssef, Luke Gammon ... Adrian Biddle
    Research Article

    Cancer stem cells (CSCs) undergo epithelial-mesenchymal transition (EMT) to drive metastatic dissemination in experimental cancer models. However, tumour cells undergoing EMT have not been observed disseminating into the tissue surrounding human tumour specimens, leaving the relevance to human cancer uncertain. We have previously identified both EpCAM and CD24 as CSC markers that, alongside the mesenchymal marker Vimentin, identify EMT CSCs in human oral cancer cell lines. This afforded the opportunity to investigate whether the combination of these three markers can identify disseminating EMT CSCs in actual human tumours. Examining disseminating tumour cells in over 12,000 imaging fields from 74 human oral tumours, we see a significant enrichment of EpCAM, CD24 and Vimentin co-stained cells disseminating beyond the tumour body in metastatic specimens. Through training an artificial neural network, these predict metastasis with high accuracy (cross-validated accuracy of 87-89%). In this study, we have observed single disseminating EMT CSCs in human oral cancer specimens, and these are highly predictive of metastatic disease.